<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000960</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>395</s160></s100><s200><s210>1</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 1Lys Lys Lys Lys1</s400><s200><s210>2</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 2Arg Arg Arg Arg1</s400><s200><s210>3</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 3Lys Lys Lys Lys Lys1               5</s400><s200><s210>4</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 4Gly Ala Asp Gly Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>5</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 5Gly Ala Cys Gly Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>6</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 6Gly Ala Val Gly Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>7</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 7Gly Ala Asp Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>8</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 8Gly Ala Cys Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>9</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 9Gly Ala Val Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>10</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 10Lys Leu Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>11</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 11Phe Leu Val Val Val Gly Ala Cys Gly Leu1               5                   10</s400><s200><s210>12</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 12Phe Met Val Val Val Gly Ala Cys Gly Ile1               5                   10</s400><s200><s210>13</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 13Phe Leu Val Val Val Gly Ala Cys Gly Ile1               5                   10</s400><s200><s210>14</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 14Phe Met Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>15</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 15Phe Leu Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>16</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 16Met Leu Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>17</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 17Phe Met Val Val Val Gly Ala Cys Gly Leu1               5                   10</s400><s200><s210>18</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 18Tyr Leu Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>19</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 19Lys Met Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>20</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 20Tyr Met Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>21</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 21Met Met Val Val Val Gly Ala Cys Gly Val1               5                   10</s400><s200><s210>22</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 22Asp Thr Ala Gly His Glu Glu Tyr1               5</s400><s200><s210>23</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 23Thr Ala Gly His Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>24</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 24Asp Ile Leu Asp Thr Ala Gly His Glu1               5</s400><s200><s210>25</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 25Asp Ile Leu Asp Thr Ala Gly His1               5</s400><s200><s210>26</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 26Ile Leu Asp Thr Ala Gly His Glu Glu1               5</s400><s200><s210>27</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 27Ile Leu Asp Thr Ala Gly His Glu1               5</s400><s200><s210>28</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 28Asp Ile Leu Asp Thr Ala Gly His Glu Glu Tyr1               5                   10</s400><s200><s210>29</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 29Asp Thr Ala Gly His Glu Glu Tyr Ser1               5</s400><s200><s210>30</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 30Leu Leu Asp Ile Leu Asp Thr Ala Gly His1               5                   10</s400><s200><s210>31</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 31Asp Ile Leu Asp Thr Ala Gly Arg Glu1               5</s400><s200><s210>32</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 32Asp Ile Leu Asp Thr Ala Gly Arg1               5</s400><s200><s210>33</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 33Ile Leu Asp Thr Ala Gly Arg Glu Glu1               5</s400><s200><s210>34</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 34Ile Leu Asp Thr Ala Gly Arg Glu1               5</s400><s200><s210>35</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 35Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Arg1               5                   10</s400><s200><s210>36</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 36Thr Ala Gly Arg Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>37</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 37Arg Glu Glu Tyr Ser Ala Met Arg Asp1               5</s400><s200><s210>38</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 38Asp Thr Ala Gly Lys Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>39</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 39Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Lys1               5                   10</s400><s200><s210>40</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 40Asp Thr Ala Gly Lys Glu Glu Tyr1               5</s400><s200><s210>41</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 41Leu Leu Asp Ile Leu Asp Thr Ala Gly Lys1               5                   10</s400><s200><s210>42</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 42Ile Leu Asp Thr Ala Gly Lys Glu1               5</s400><s200><s210>43</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 43Ile Leu Asp Thr Ala Gly Lys Glu Glu1               5</s400><s200><s210>44</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 44Asp Thr Ala Gly Leu Glu Glu Tyr1               5</s400><s200><s210>45</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 45Ile Leu Asp Thr Ala Gly Leu Glu1               5</s400><s200><s210>46</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 46Asp Ile Leu Asp Thr Ala Gly Leu1               5</s400><s200><s210>47</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 47Ile Leu Asp Thr Ala Gly Leu Glu Glu1               5</s400><s200><s210>48</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 48Gly Leu Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr1               5                   10</s400><s200><s210>49</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 49Leu Leu Asp Ile Leu Asp Thr Ala Gly Leu Glu1               5                   10</s400><s200><s210>50</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 50Leu Asp Ile Leu Asp Thr Ala Gly Leu1               5</s400><s200><s210>51</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 51Asp Ile Leu Asp Thr Ala Gly Leu Glu1               5</s400><s200><s210>52</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 52Asp Ile Leu Asp Thr Ala Gly Leu Glu Glu Tyr1               5                   10</s400><s200><s210>53</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 53Ala Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>54</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 54Gly Ala Ala Gly Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>55</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 55Ala Ala Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>56</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 56Cys Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>57</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 57Ala Cys Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>58</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 58Asp Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>59</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 59Ala Asp Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>60</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 60Asp Gly Val Gly Lys Ser Ala Leu Thr Ile1               5                   10</s400><s200><s210>61</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 61Gly Ala Arg Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>62</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 62Lys Leu Val Val Val Gly Ala Arg Gly Val1               5                   10</s400><s200><s210>63</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 63Val Val Val Gly Ala Arg Gly Val1               5</s400><s200><s210>64</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 64Ser Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>65</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 65Val Val Val Gly Ala Ser Gly Val Gly Lys1               5                   10</s400><s200><s210>66</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 66Gly Ala Ser Gly Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>67</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 67Val Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>68</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 68Val Val Val Gly Ala Gly Cys Val Gly Lys1               5                   10</s400><s200><s210>69</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 69Lys Leu Val Val Val Gly Ala Gly Cys1               5</s400><s200><s210>70</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 70Gly Asp Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>71</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 71Asp Val Gly Lys Ser Ala Leu Thr Ile1               5</s400><s200><s210>72</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 72Val Val Val Gly Ala Gly Asp Val Gly Lys1               5                   10</s400><s200><s210>73</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 73Thr Ala Gly Lys Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>74</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 74Asp Thr Ala Gly His Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>75</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 75Thr Ala Gly His Glu Glu Tyr Ser Ala1               5</s400><s200><s210>76</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 76Asp Thr Ala Gly Arg Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>77</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 77Thr Ala Gly Lys Glu Glu Tyr Ser Ala1               5</s400><s200><s210>78</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 78Ala Ala Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>79</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 79Ala Gly Cys Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>80</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 80Ala Gly Asp Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>81</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 81Ala Gly Lys Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>82</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 82Ala Gly Val Gly Lys Ser Ala Leu Thr Ile1               5                   10</s400><s200><s210>83</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 83Ala Arg Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>84</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 84Ala Ser Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>85</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 85Ala Ser Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>86</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 86Ala Val Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>87</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 87Cys Val Gly Lys Ser Ala Leu Thr Ile1               5</s400><s200><s210>88</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 88Asp Ile Leu Asp Thr Ala Gly Lys1               5</s400><s200><s210>89</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 89Asp Ile Leu Asp Thr Ala Gly Arg Glu Glu Tyr1               5                   10</s400><s200><s210>90</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 90Asp Thr Ala Gly His Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>91</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 91Asp Thr Ala Gly Lys Glu Glu Tyr Ser1               5</s400><s200><s210>92</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 92Asp Thr Ala Gly Lys Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>93</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 93Asp Thr Ala Gly Leu Glu Glu Tyr Ser1               5</s400><s200><s210>94</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 94Asp Thr Ala Gly Leu Glu Glu Tyr Ser Ala1               5                   10</s400><s200><s210>95</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 95Asp Thr Ala Gly Leu Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>96</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 96Asp Thr Ala Gly Arg Glu Glu Tyr Ser1               5</s400><s200><s210>97</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 97Asp Thr Ala Gly Arg Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>98</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 98Gly Ala Ala Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>99</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 99Gly Ala Asp Gly Val Gly Lys Ser1               5</s400><s200><s210>100</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 100Gly Ala Gly Asp Val Gly Lys Ser Ala1               5</s400><s200><s210>101</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 101Gly Ala Gly Asp Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>102</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 102Gly Ala Ser Gly Val Gly Lys Ser Ala1               5</s400><s200><s210>103</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 103Gly Cys Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>104</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 104Gly Cys Val Gly Lys Ser Ala Leu Thr Ile1               5                   10</s400><s200><s210>105</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 105Gly His Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>106</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 106Gly Lys Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>107</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 107Gly Leu Glu Glu Tyr Ser Ala Met Arg1               5</s400><s200><s210>108</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 108Gly Arg Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>109</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 109Gly Arg Glu Glu Tyr Ser Ala Met Arg1               5</s400><s200><s210>110</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 110His Glu Glu Tyr Ser Ala Met Arg Asp1               5</s400><s200><s210>111</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 111Lys Glu Glu Tyr Ser Ala Met Arg Asp1               5</s400><s200><s210>112</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 112Lys Leu Val Val Val Gly Ala Ser Gly1               5</s400><s200><s210>113</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 113Leu Asp Ile Leu Asp Thr Ala Gly Arg1               5</s400><s200><s210>114</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 114Leu Glu Glu Tyr Ser Ala Met Arg Asp1               5</s400><s200><s210>115</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 115Leu Val Val Val Gly Ala Arg Gly Val1               5</s400><s200><s210>116</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 116Leu Val Val Val Gly Ala Ser Gly Val1               5</s400><s200><s210>117</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 117Arg Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr1               5                   10</s400><s200><s210>118</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 118Arg Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>119</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 119Thr Ala Gly Leu Glu Glu Tyr Ser Ala1               5</s400><s200><s210>120</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 120Thr Glu Tyr Lys Leu Val Val Val Gly Ala Ala1               5                   10</s400><s200><s210>121</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 121Val Gly Ala Ala Gly Val Gly Lys Ser Ala1               5                   10</s400><s200><s210>122</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 122Val Gly Ala Asp Gly Val Gly Lys1               5</s400><s200><s210>123</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 123Val Gly Ala Ser Gly Val Gly Lys Ser Ala1               5                   10</s400><s200><s210>124</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 124Val Gly Val Gly Lys Ser Ala Leu Thr Ile1               5                   10</s400><s200><s210>125</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 125Val Val Val Gly Ala Ala Gly Val1               5</s400><s200><s210>126</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 126Val Val Val Gly Ala Val Gly Val1               5</s400><s200><s210>127</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 127Tyr Lys Leu Val Val Val Gly Ala Cys1               5</s400><s200><s210>128</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 128Tyr Lys Leu Val Val Val Gly Ala Asp1               5</s400><s200><s210>129</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 129Tyr Lys Leu Val Val Val Gly Ala Arg1               5</s400><s200><s210>130</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 130Asp Ile Leu Asp Thr Ala Gly Lys Glu1               5</s400><s200><s210>131</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 131Ile Asp Ile Ile Met Lys Ile Arg Asn Ala1               5                   10</s400><s200><s210>132</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 132Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe1               5                   10                  15Phe Phe Phe Phe Ile Ile Phe Phe Ile Phe Phe Trp Met Cys            20                  25                  30</s400><s200><s210>133</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 133Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe Phe1               5                   10                  15Phe Phe Phe Phe Phe Phe Phe Phe Ala Ala Phe Trp Phe Trp            20                  25                  30</s400><s200><s210>134</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 134Ile Phe Phe Ile Phe Phe Ile Ile Phe Phe Phe Phe Phe Phe Phe Phe1               5                   10                  15Phe Phe Phe Phe Ile Ile Ile Ile Ile Ile Ile Trp Glu Cys            20                  25                  30</s400><s200><s210>135</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 135Phe Ile Phe Phe Phe Ile Ile Phe Phe Phe Phe Phe Ile Phe Phe Phe1               5                   10                  15Phe Phe Ile Phe Ile Ile Ile Ile Ile Ile Phe Trp Glu Cys            20                  25                  30</s400><s200><s210>136</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 136Thr Glu Tyr Lys Leu Val1               5</s400><s200><s210>137</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 137Trp Gln Ala Gly Ile Leu Ala Arg1               5</s400><s200><s210>138</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 138His Ser Tyr Thr Thr Ala Glu1               5</s400><s200><s210>139</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 139Pro Leu Thr Glu Glu Lys Ile Lys1               5</s400><s200><s210>140</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 140Gly Ala Leu His Phe Lys Pro Gly Ser Arg1               5                   10</s400><s200><s210>141</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 141Arg Arg Ala Asn Lys Asp Ala Thr Ala Glu1               5                   10</s400><s200><s210>142</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 142Lys Ala Phe Ile Ser His Glu Glu Lys Arg1               5                   10</s400><s200><s210>143</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 143Thr Asp Leu Ser Ser Arg Phe Ser Lys Ser1               5                   10</s400><s200><s210>144</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 144Phe Asp Leu Gly Gly Gly Thr Phe Asp Val1               5                   10</s400><s200><s210>145</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 145Cys Leu Leu Leu His Tyr Ser Val Ser Lys1               5                   10</s400><s200><s210>146</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 146Lys Lys Lys Lys Ile Ile Met Lys Ile Arg Asn Ala1               5                   10</s400><s200><s210>147</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 147Met Thr Glu Tyr Lys Leu Val Val Val1               5</s400><s200><s210>148</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 148Lys Lys Asn Lys Lys Asp Asp Ile1               5</s400><s200><s210>149</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 149Lys Lys Asn Lys Lys Asp Asp Ile Lys Asp1               5                   10</s400><s200><s210>150</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 150Ala Gly Asn Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp1               5                   10                  15Asp Asp Asp Asp Lys Lys Asp Lys Asp Asp Asp Asp Asp Asp            20                  25                  30</s400><s200><s210>151</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 151Ala Gly Asn Lys Lys Lys Lys Lys Lys Lys Asn Asn Asn Asn Asn Asn1               5                   10                  15Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn            20                  25                  30</s400><s200><s210>152</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 152Ala Gly Arg Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp1               5                   10                  15Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp            20                  25                  30</s400><s200><s210>153</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 153Ser Ala Leu Thr Ile1               5</s400><s200><s210>154</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 154Ser Ala Leu Thr Ile Gln Leu1               5</s400><s200><s210>155</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 155Gly Lys Ser Ala Leu Thr Ile Gln Leu1               5</s400><s200><s210>156</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 156Gly Lys Ser Ala Leu Thr Ile1               5</s400><s200><s210>157</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 157Gln Gly Gln Asn Leu Lys Tyr Gln1               5</s400><s200><s210>158</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 158Ile Leu Gly Val Leu Leu Leu Ile1               5</s400><s200><s210>159</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 159Glu Lys Glu Gly Lys Ile Ser Lys1               5</s400><s200><s210>160</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 160Ala Ala Ser Asp Phe Ile Phe Leu Val Thr1               5                   10</s400><s200><s210>161</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 161Lys Glu Leu Lys Gln Val Ala Ser Pro Phe1               5                   10</s400><s200><s210>162</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 162Lys Lys Lys Leu Ile Asn Glu Lys Lys Glu1               5                   10</s400><s200><s210>163</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 163Lys Lys Cys Asp Ile Ser Leu Gln Phe Phe1               5                   10</s400><s200><s210>164</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 164Lys Ser Thr Ala Gly Asp Thr His Leu Gly1               5                   10</s400><s200><s210>165</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 165Ala Thr Phe Tyr Val Ala Val Thr Val Pro1               5                   10</s400><s200><s210>166</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 166Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr Asp Pro1               5                   10                  15Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly            20                  25                  30</s400><s200><s210>167</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 167Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr Asp Pro Thr1               5                   10                  15Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly Glu            20                  25                  30</s400><s200><s210>168</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 168Lys Lys Lys Lys Lys Pro Lys Arg Asp Gly Tyr Met Phe Leu Lys Ala1               5                   10                  15Glu Ser Lys Ile Met Phe Ala Thr            20</s400><s200><s210>169</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 169Lys Lys Lys Lys Tyr Met Phe Leu Lys Ala Glu Ser Lys Ile Met Phe1               5                   10                  15Ala Thr Leu Gln Arg Ser Ser            20</s400><s200><s210>170</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 170Lys Lys Lys Lys Lys Ala Glu Ser Lys Ile Met Phe Ala Thr Leu Gln1               5                   10                  15Arg Ser Ser Leu Trp Cys Leu            20</s400><s200><s210>171</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 171Lys Lys Lys Lys Lys Ile Met Phe Ala Thr Leu Gln Arg Ser Ser Leu1               5                   10                  15Trp Cys Leu Cys Ser Asn His            20</s400><s200><s210>172</s210><s211>21</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 172Lys Lys Lys Lys Met Phe Ala Thr Leu Gln Arg Ser Ser Leu Trp Cys1               5                   10                  15Leu Cys Ser Asn His            20</s400><s200><s210>173</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 173Met Leu Thr Gly Pro Pro Ala Arg Val1               5</s400><s200><s210>174</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 174Ser Met Leu Thr Gly Pro Pro Ala Arg Val1               5                   10</s400><s200><s210>175</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 175Val Leu Pro Glu Pro His Leu Ala Leu1               5</s400><s200><s210>176</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 176Lys Pro Lys Arg Asp Gly Tyr Met Phe1               5</s400><s200><s210>177</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 177Lys Pro Lys Arg Asp Gly Tyr Met Phe Leu1               5                   10</s400><s200><s210>178</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 178Glu Ser Lys Ile Met Phe Ala Thr Leu1               5</s400><s200><s210>179</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 179Lys Arg Asp Gly Tyr Met Phe Leu1               5</s400><s200><s210>180</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 180Pro Ala Val Pro Phe Asp Leu His Phe1               5</s400><s200><s210>181</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 181Ala Glu Ser Lys Ile Met Phe Ala Thr Leu1               5                   10</s400><s200><s210>182</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 182Phe Ala Thr Leu Gln Arg Ser Ser Leu1               5</s400><s200><s210>183</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 183Ala Arg Val Pro Ala Val Pro Phe Asp1               5</s400><s200><s210>184</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 184Ile Met Lys Pro Lys Arg Asp Gly Tyr1               5</s400><s200><s210>185</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 185Asp Gly Tyr Met Phe Leu Lys Ala1               5</s400><s200><s210>186</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 186Met Phe Leu Lys Ala Glu Ser Lys Ile Met Phe1               5                   10</s400><s200><s210>187</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 187Leu Thr Gly Pro Pro Ala Arg Val1               5</s400><s200><s210>188</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 188Ala Arg Val Pro Ala Val Pro Phe1               5</s400><s200><s210>189</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 189Ser Met Leu Thr Gly Pro Pro Ala Arg1               5</s400><s200><s210>190</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 190Arg Val Pro Ala Val Pro Phe Asp Leu1               5</s400><s200><s210>191</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 191Leu Thr Gly Pro Pro Ala Arg Val Pro1               5</s400><s200><s210>192</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 192Val Val Val Gly Ala Ala Gly Val Gly Lys1               5                   10</s400><s200><s210>193</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 193Val Val Val Gly Ala Ala Gly Val Gly1               5</s400><s200><s210>194</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 194Val Val Gly Ala Ala Gly Val Gly Lys1               5</s400><s200><s210>195</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 195Val Val Gly Ala Ala Gly Val Gly1               5</s400><s200><s210>196</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 196Val Gly Ala Ala Gly Val Gly Lys1               5</s400><s200><s210>197</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 197Val Val Val Gly Ala Cys Gly Val Gly Lys1               5                   10</s400><s200><s210>198</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 198Val Val Val Gly Ala Cys Gly Val Gly1               5</s400><s200><s210>199</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 199Val Val Val Gly Ala Cys Gly Val1               5</s400><s200><s210>200</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 200Val Val Gly Ala Cys Gly Val Gly Lys1               5</s400><s200><s210>201</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 201Val Val Gly Ala Cys Gly Val Gly1               5</s400><s200><s210>202</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 202Val Gly Ala Cys Gly Val Gly Lys1               5</s400><s200><s210>203</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 203Val Val Val Gly Ala Asp Gly Val Gly Lys1               5                   10</s400><s200><s210>204</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 204Val Val Val Gly Ala Asp Gly Val Gly1               5</s400><s200><s210>205</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 205Val Val Val Gly Ala Asp Gly Val1               5</s400><s200><s210>206</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 206Val Val Gly Ala Asp Gly Val Gly Lys1               5</s400><s200><s210>207</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 207Val Val Gly Ala Asp Gly Val Gly1               5</s400><s200><s210>208</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 208Val Val Val Gly Ala Arg Gly Val Gly Lys1               5                   10</s400><s200><s210>209</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 209Val Val Val Gly Ala Arg Gly Val Gly1               5</s400><s200><s210>210</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 210Val Val Gly Ala Arg Gly Val Gly Lys1               5</s400><s200><s210>211</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 211Val Val Gly Ala Arg Gly Val Gly1               5</s400><s200><s210>212</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 212Val Gly Ala Arg Gly Val Gly Lys1               5</s400><s200><s210>213</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 213Val Val Val Gly Ala Ser Gly Val Gly1               5</s400><s200><s210>214</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 214Val Val Val Gly Ala Ser Gly Val1               5</s400><s200><s210>215</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 215Val Val Gly Ala Ser Gly Val Gly Lys1               5</s400><s200><s210>216</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 216Val Val Gly Ala Ser Gly Val Gly1               5</s400><s200><s210>217</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 217Val Gly Ala Ser Gly Val Gly Lys1               5</s400><s200><s210>218</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 218Val Val Val Gly Ala Val Gly Val Gly Lys1               5                   10</s400><s200><s210>219</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 219Val Val Val Gly Ala Val Gly Val Gly1               5</s400><s200><s210>220</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 220Val Val Gly Ala Val Gly Val Gly Lys1               5</s400><s200><s210>221</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 221Val Val Gly Ala Val Gly Val Gly1               5</s400><s200><s210>222</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 222Val Gly Ala Val Gly Val Gly Lys1               5</s400><s200><s210>223</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 223Lys Lys Lys Lys Lys Lys Lys1               5</s400><s200><s210>224</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 224Lys Lys Lys Lys Lys Lys Lys Lys1               5</s400><s200><s210>225</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 225Lys Thr Glu Tyr1</s400><s200><s210>226</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 226Lys Thr Glu Tyr Lys1               5</s400><s200><s210>227</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 227Lys Thr Glu Tyr Lys Leu1               5</s400><s200><s210>228</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 228Lys Thr Glu Tyr Lys Leu Val1               5</s400><s200><s210>229</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 229Lys Thr Glu Tyr Lys Leu Val Val1               5</s400><s200><s210>230</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 230Lys Thr Glu Tyr Lys Leu Val Val Val1               5</s400><s200><s210>231</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 231Lys Lys Thr Glu Tyr1               5</s400><s200><s210>232</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 232Lys Lys Thr Glu Tyr Lys1               5</s400><s200><s210>233</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 233Lys Lys Thr Glu Tyr Lys Leu1               5</s400><s200><s210>234</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 234Lys Lys Thr Glu Tyr Lys Leu Val1               5</s400><s200><s210>235</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 235Lys Lys Thr Glu Tyr Lys Leu Val Val1               5</s400><s200><s210>236</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 236Lys Lys Thr Glu Tyr Lys Leu Val Val Val1               5                   10</s400><s200><s210>237</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 237Lys Lys Lys Thr Glu Tyr1               5</s400><s200><s210>238</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 238Lys Lys Lys Thr Glu Tyr Lys1               5</s400><s200><s210>239</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 239Lys Lys Lys Thr Glu Tyr Lys Leu1               5</s400><s200><s210>240</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 240Lys Lys Lys Thr Glu Tyr Lys Leu Val1               5</s400><s200><s210>241</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 241Lys Lys Lys Thr Glu Tyr Lys Leu Val Val1               5                   10</s400><s200><s210>242</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 242Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val1               5                   10</s400><s200><s210>243</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 243Lys Lys Lys Lys Thr Glu Tyr1               5</s400><s200><s210>244</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 244Lys Lys Lys Lys Thr Glu Tyr Lys1               5</s400><s200><s210>245</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 245Lys Lys Lys Lys Thr Glu Tyr Lys Leu1               5</s400><s200><s210>246</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 246Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val1               5                   10</s400><s200><s210>247</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 247Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val Val1               5                   10</s400><s200><s210>248</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 248Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val1               5                   10</s400><s200><s210>249</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 249Thr Glu Tyr Lys1</s400><s200><s210>250</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 250Thr Glu Tyr Lys Leu1               5</s400><s200><s210>251</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 251Thr Glu Tyr Lys Leu Val Val1               5</s400><s200><s210>252</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 252Thr Glu Tyr Lys Leu Val Val Val1               5</s400><s200><s210>253</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 253Ser Ala Leu Thr Ile Lys1               5</s400><s200><s210>254</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 254Ser Ala Leu Thr Ile Gln Leu Lys1               5</s400><s200><s210>255</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 255Gly Lys Ser Ala Leu Thr Ile Gln Leu Lys1               5                   10</s400><s200><s210>256</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 256Gly Lys Ser Ala Leu Thr Ile Lys1               5</s400><s200><s210>257</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 257Ser Ala Leu Thr Ile Lys Lys1               5</s400><s200><s210>258</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 258Ser Ala Leu Thr Ile Gln Leu Lys Lys1               5</s400><s200><s210>259</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 259Gly Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys1               5                   10</s400><s200><s210>260</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 260Gly Lys Ser Ala Leu Thr Ile Lys Lys1               5</s400><s200><s210>261</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 261Ser Ala Leu Thr Ile Lys Lys Lys1               5</s400><s200><s210>262</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 262Ser Ala Leu Thr Ile Gln Leu Lys Lys Lys1               5                   10</s400><s200><s210>263</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 263Gly Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys Lys1               5                   10</s400><s200><s210>264</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 264Gly Lys Ser Ala Leu Thr Ile Lys Lys Lys1               5                   10</s400><s200><s210>265</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 265Ser Ala Leu Thr Ile Lys Lys Lys Lys1               5</s400><s200><s210>266</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 266Ser Ala Leu Thr Ile Gln Leu Lys Lys Lys Lys1               5                   10</s400><s200><s210>267</s210><s211>13</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 267Gly Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys Lys Lys1               5                   10</s400><s200><s210>268</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 268Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>269</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 269Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>270</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 270Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>271</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 271Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>272</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 272Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>273</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 273Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>274</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 274Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>275</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 275Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>276</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 276Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val1               5                   10                  15Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>277</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 277Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val1               5                   10                  15Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>278</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 278Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val1               5                   10                  15Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>279</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 279Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val1               5                   10                  15Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>280</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 280Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly1               5                   10                  15Val Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>281</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 281Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly1               5                   10                  15Val Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>282</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 282Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly1               5                   10                  15Val Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>283</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 283Lys Lys Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly1               5                   10                  15Val Gly Lys Ser Ala Leu Thr Ile Gln Leu            20                  25</s400><s200><s210>284</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 284Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys            20                  25</s400><s200><s210>285</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 285Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys            20                  25</s400><s200><s210>286</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 286Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys            20                  25</s400><s200><s210>287</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 287Lys Lys Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly1               5                   10                  15Lys Ser Ala Leu Thr Ile Gln Leu Lys Lys            20                  25</s400><s200><s210>288</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 288Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys            20</s400><s200><s210>289</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 289Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys            20</s400><s200><s210>290</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 290Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys            20</s400><s200><s210>291</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 291Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys            20</s400><s200><s210>292</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 292Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys            20</s400><s200><s210>293</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 293Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys            20</s400><s200><s210>294</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 294Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys            20</s400><s200><s210>295</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 295Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys            20</s400><s200><s210>296</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 296Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys            20                  25</s400><s200><s210>297</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 297Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys            20                  25</s400><s200><s210>298</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 298Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys            20                  25</s400><s200><s210>299</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 299Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys            20                  25</s400><s200><s210>300</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 300Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys Lys            20                  25</s400><s200><s210>301</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 301Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys Lys            20                  25</s400><s200><s210>302</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 302Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys Lys            20                  25</s400><s200><s210>303</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 303Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile Gln Leu Lys Lys Lys Lys            20                  25</s400><s200><s210>304</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 304Ala Leu Asn Ser Glu Ala Leu Ser Val1               5</s400><s200><s210>305</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(10)</s222><s223>This region may encompass 5-10 residues</s223></s220><s220><s223>See specification as filed for detailed      description of substitutions and preferred embodiments</s223></s220></s200><s400> 305Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys1               5                   10</s400><s200><s210>306</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(7)</s222><s223>This region may encompass 4-7 residues</s223></s220><s220><s223>See specification as filed for detailed      description of substitutions and preferred embodiments</s223></s220></s200><s400> 306Arg Arg Arg Arg Arg Arg Arg1               5</s400><s200><s210>307</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 307Arg Arg Arg Arg Arg Arg Arg Arg1               5</s400><s200><s210>308</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(1)..(7)</s222><s223>This region may encompass 5-10 residues</s223></s220><s220><s223>See specification as filed for detailed      description of substitutions and preferred embodiments</s223></s220></s200><s400> 308Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg1               5                   10</s400><s200><s210>309</s210><s211>62</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 309Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr            20                  25                  30Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly        35                  40                  45Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu    50                  55                  60</s400><s200><s210>310</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 310Leu Val Val Val Gly Ala Cys Gly Val1               5</s400><s200><s210>311</s210><s211>62</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 311Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr            20                  25                  30Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly        35                  40                  45Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu    50                  55                  60</s400><s200><s210>312</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 312Lys Leu Val Val Val Gly Ala Asp Gly Val1               5                   10</s400><s200><s210>313</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 313Leu Val Val Val Gly Ala Asp Gly Val1               5</s400><s200><s210>314</s210><s211>62</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 314Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr            20                  25                  30Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly        35                  40                  45Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu    50                  55                  60</s400><s200><s210>315</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 315Lys Leu Val Val Val Gly Ala Val Gly Val1               5                   10</s400><s200><s210>316</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 316Leu Val Val Val Gly Ala Val Gly Val1               5</s400><s200><s210>317</s210><s211>101</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 317Ala Gly Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn1               5                   10                  15His Phe Val Asp Glu Tyr Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys            20                  25                  30Gln Val Val Ile Asp Gly Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr        35                  40                  45Ala Gly His Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr Met Arg Thr    50                  55                  60Gly Glu Gly Phe Leu Cys Val Phe Ala Ile Asn Asn Thr Lys Ser Phe65                  70                  75                  80Glu Asp Ile His His Tyr Arg Glu Gln Ile Lys Arg Val Lys Asp Ser                85                  90                  95Glu Asp Val Pro Met            100</s400><s200><s210>318</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 318Ile Leu Asp Thr Ala Gly His Glu Glu Tyr1               5                   10</s400><s200><s210>319</s210><s211>101</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 319Ala Gly Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn1               5                   10                  15His Phe Val Asp Glu Tyr Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys            20                  25                  30Gln Val Val Ile Asp Gly Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr        35                  40                  45Ala Gly Leu Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr Met Arg Thr    50                  55                  60Gly Glu Gly Phe Leu Cys Val Phe Ala Ile Asn Asn Thr Lys Ser Phe65                  70                  75                  80Glu Asp Ile His His Tyr Arg Glu Gln Ile Lys Arg Val Lys Asp Ser                85                  90                  95Glu Asp Val Pro Met            100</s400><s200><s210>320</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 320Ile Leu Asp Thr Ala Gly Leu Glu Glu Tyr1               5                   10</s400><s200><s210>321</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 321Leu Leu Asp Ile Leu Asp Thr Ala Gly Leu1               5                   10</s400><s200><s210>322</s210><s211>101</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 322Ala Gly Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn1               5                   10                  15His Phe Val Asp Glu Tyr Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys            20                  25                  30Gln Val Val Ile Asp Gly Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr        35                  40                  45Ala Gly Lys Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr Met Arg Thr    50                  55                  60Gly Glu Gly Phe Leu Cys Val Phe Ala Ile Asn Asn Ser Lys Ser Phe65                  70                  75                  80Ala Asp Ile Asn Leu Tyr Arg Glu Gln Ile Lys Arg Val Lys Asp Ser                85                  90                  95Asp Asp Val Pro Met            100</s400><s200><s210>323</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 323Ile Leu Asp Thr Ala Gly Lys Glu Glu Tyr1               5                   10</s400><s200><s210>324</s210><s211>101</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 324Ala Gly Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn1               5                   10                  15His Phe Val Asp Glu Tyr Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys            20                  25                  30Gln Val Val Ile Asp Gly Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr        35                  40                  45Ala Gly Arg Glu Glu Tyr Ser Ala Met Arg Asp Gln Tyr Met Arg Thr    50                  55                  60Gly Glu Gly Phe Leu Cys Val Phe Ala Ile Asn Asn Ser Lys Ser Phe65                  70                  75                  80Ala Asp Ile Asn Leu Tyr Arg Glu Gln Ile Lys Arg Val Lys Asp Ser                85                  90                  95Asp Asp Val Pro Met            100</s400><s200><s210>325</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 325Ile Leu Asp Thr Ala Gly Arg Glu Glu Tyr1               5                   10</s400><s200><s210>326</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 326Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly His Glu Glu Tyr Ser1               5                   10                  15Ala Met Arg Asp Gln Tyr Met            20</s400><s200><s210>327</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 327Ala Gly His Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>328</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 328Leu Asp Thr Ala Gly His Glu Glu Tyr1               5</s400><s200><s210>329</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 329Asp Thr Ala Gly His Glu Glu Tyr Ser Ala1               5                   10</s400><s200><s210>330</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 330Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Arg Glu Glu Tyr Ser1               5                   10                  15Ala Met Arg Asp Gln Tyr Met            20</s400><s200><s210>331</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 331Asp Thr Ala Gly Arg Glu Glu Tyr1               5</s400><s200><s210>332</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 332Ala Gly Arg Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>333</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 333Thr Ala Gly Arg Glu Glu Tyr Ser Ala1               5</s400><s200><s210>334</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 334Leu Leu Asp Ile Leu Asp Thr Ala Gly Arg1               5                   10</s400><s200><s210>335</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 335Ala Gly Arg Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>336</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 336Leu Asp Thr Ala Gly Arg Glu Glu Tyr1               5</s400><s200><s210>337</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 337Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Lys Glu Glu Tyr Ser1               5                   10                  15Ala Met Arg Asp Gln Tyr Met            20</s400><s200><s210>338</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 338Ala Gly Lys Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>339</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 339Leu Asp Thr Ala Gly Lys Glu Glu Tyr1               5</s400><s200><s210>340</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 340Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Leu Glu Glu Tyr Ser1               5                   10                  15Ala Met Arg Asp Gln Tyr Met            20</s400><s200><s210>341</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 341Asp Thr Ala Gly Leu Glu Glu Tyr Ser Ala Met1               5                   10</s400><s200><s210>342</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 342Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Leu1               5                   10</s400><s200><s210>343</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 343Leu Asp Thr Ala Gly Leu Glu Glu Tyr1               5</s400><s200><s210>344</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 344Ala Gly Leu Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>345</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 345Ala Gly Leu Glu Glu Tyr Ser Ala Met Arg1               5                   10</s400><s200><s210>346</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 346Gly Leu Glu Glu Tyr Ser Ala Met1               5</s400><s200><s210>347</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 347Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Ala Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>348</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 348Leu Val Val Val Gly Ala Ala Gly Val1               5</s400><s200><s210>349</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 349Lys Leu Val Val Val Gly Ala Ala Gly Val1               5                   10</s400><s200><s210>350</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 350Tyr Lys Leu Val Val Val Gly Ala Ala1               5</s400><s200><s210>351</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 351Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>352</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 352Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>353</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 353Val Gly Ala Asp Gly Val Gly Lys Ser Ala1               5                   10</s400><s200><s210>354</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 354Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>355</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 355Gly Ala Arg Gly Val Gly Lys Ser Ala Leu1               5                   10</s400><s200><s210>356</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 356Arg Gly Val Gly Lys Ser Ala Leu Thr Ile1               5                   10</s400><s200><s210>357</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 357Lys Leu Val Val Val Gly Ala Arg1               5</s400><s200><s210>358</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 358Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Ser Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>359</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 359Lys Leu Val Val Val Gly Ala Ser Gly Val1               5                   10</s400><s200><s210>360</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 360Ser Gly Val Gly Lys Ser Ala Leu Thr Ile1               5                   10</s400><s200><s210>361</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 361Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>362</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 362Ala Val Gly Val Gly Lys Ser Ala Leu1               5</s400><s200><s210>363</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 363Tyr Lys Leu Val Val Val Gly Ala Val1               5</s400><s200><s210>364</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 364Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Cys Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>365</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 365Val Val Gly Ala Gly Cys Val Gly Lys1               5</s400><s200><s210>366</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 366Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Asp Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu            20</s400><s200><s210>367</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 367Val Val Gly Ala Gly Asp Val Gly Lys1               5</s400><s200><s210>368</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 368Ala Leu Asn Ser Glu Ala Leu Ser Val Val1               5                   10</s400><s200><s210>369</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 369Met Ala Leu Asn Ser Glu Ala Leu Ser Val1               5                   10</s400><s200><s210>370</s210><s211>71</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 370Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1               5                   10                  15Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr            20                  25                  30Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly        35                  40                  45Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Val Val    50                  55                  60Gly Ala Asp Gly Val Gly Lys65                  70</s400><s200><s210>371</s210><s211>30</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      oligonucleotide</s223></s220></s200><s400> 371ggcggcagcg gcggcggcgg cagcggcggc                                      30</s400><s200><s210>372</s210><s211>30</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      oligonucleotide</s223></s220></s200><s400> 372ggcggcagcc tgggcggcgg cggcagcggc                                      30</s400><s200><s210>373</s210><s211>12</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      oligonucleotide</s223></s220></s200><s400> 373ggcgtcggca cc                                                         12</s400><s200><s210>374</s210><s211>12</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      oligonucleotide</s223></s220></s200><s400> 374cagctgggcc tg                                                         12</s400><s200><s210>375</s210><s211>12</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      oligonucleotide</s223></s220></s200><s400> 375caactgggat tg                                                         12</s400><s200><s210>376</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      6xHis tag</s223></s220></s200><s400> 376His His His His His His1               5</s400><s200><s210>377</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 377Ala Val Gly Ile Thr Tyr Thr Trp Thr Arg Leu Tyr Ala Ser Val Leu1               5                   10                  15Thr Gly Ser Leu Val Ser Lys Thr Lys Lys            20                  25</s400><s200><s210>378</s210><s211>29</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 378Ile Gln Lys Ile Ser Phe Phe Asp Gly Phe Glu Val Gly Phe Asn Phe1               5                   10                  15Arg Thr Leu Gln Pro Asn Gly Leu Leu Phe Tyr Tyr Thr            20                  25</s400><s200><s210>379</s210><s211>28</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 379Gly Ile Pro Val His Leu Glu Leu Ala Ser Met Thr Asn Met Glu Leu1               5                   10                  15Met Ser Ser Ile Val His Gln Gln Val Phe Pro Thr            20                  25</s400><s200><s210>380</s210><s211>28</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 380Gly Arg Val Leu Glu Leu Phe Arg Ala Ala Gln Leu Ala Asn Asp Val1               5                   10                  15Val Leu Gln Ile Met Glu Leu Cys Gly Ala Thr Arg            20                  25</s400><s200><s210>381</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 381Lys Ala Arg Asp Glu Thr Ala Ala Leu Leu Asn Ser Ala Val Leu Gly1               5                   10                  15Ala Ala Pro Leu Phe Val Pro Pro Ala Asp            20                  25</s400><s200><s210>382</s210><s211>27</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 382Arg Glu Gly Val Glu Leu Cys Pro Gly Asn Lys Tyr Glu Met Arg Arg1               5                   10                  15His Gly Thr Thr His Ser Leu Val Ile His Asp            20                  25</s400><s200><s210>383</s210><s211>27</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 383Pro Ser Lys Pro Ser Phe Gln Glu Phe Val Asp Trp Glu Asn Val Ser1               5                   10                  15Pro Glu Leu Asn Ser Thr Asp Gln Pro Phe Leu            20                  25</s400><s200><s210>384</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(6)..(6)</s222><s223>Cit</s223></s220></s200><s400> 384Lys Lys Lys Lys Val Xaa1               5</s400><s200><s210>385</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 385Gln Leu Gly Leu1</s400><s200><s210>386</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 386Gly Val Gly Thr1</s400><s200><s210>387</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 387Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys Ser1               5                   10                  15Ala Leu Thr Ile            20</s400><s200><s210>388</s210><s211>29</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 388Lys Lys Lys Lys Ile Ile Met Lys Ile Arg Asn Ala Val Val Gly Ala1               5                   10                  15Val Gly Val Gly Lys Lys Lys Asn Lys Lys Asp Asp Ile            20                  25</s400><s200><s210>389</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 389Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu1               5                   10                  15</s400><s200><s210>390</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 390Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys1               5                   10                  15</s400><s200><s210>391</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 391Trp Gln Ala Gly Ile Leu Ala Arg Val Val Gly Ala Val Gly Val Gly1               5                   10                  15Lys Gln Gly Gln Asn Leu Lys Tyr Gln            20                  25</s400><s200><s210>392</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 392His Ser Tyr Thr Thr Ala Glu Val Val Gly Ala Val Gly Val Gly Lys1               5                   10                  15Ile Leu Gly Val Leu Leu Leu Ile            20</s400><s200><s210>393</s210><s211>25</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 393Pro Leu Thr Glu Glu Lys Ile Lys Val Val Gly Ala Val Gly Val Gly1               5                   10                  15Lys Glu Lys Glu Gly Lys Ile Ser Lys            20                  25</s400><s200><s210>394</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 394Gln Leu Gly Leu Lys1               5</s400><s200><s210>395</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 395Lys Gln Leu Gly Leu1               5</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000961A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000961</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17693017</doc-number><date>20220311</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>00</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>18</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>19</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>39</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>16</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>0011</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0019</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>18</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>193</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>39</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>1611</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>00117</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001192</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001171</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001182</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>00118</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001102</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001156</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001186</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001191</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001162</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>001184</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>55522</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>55555</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>55561</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>80</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">MESOPOROUS SILICA COMPOSITIONS COMPRISING INFLAMMATORY CYTOKINES FOR MODULATING IMMUNE RESPONSES</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>15935392</doc-number><date>20180326</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>11278604</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>17693017</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>14394552</doc-number><date>20141015</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>9937249</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US2013/036827</doc-number><date>20130416</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>15935392</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>61624568</doc-number><date>20120416</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>President and Fellows of Harvard College</orgname><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Kim</last-name><first-name>Jaeyun</first-name><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Li</last-name><first-name>Weiwei Aileen</first-name><address><city>Norcross</city><state>GA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Mooney</last-name><first-name>David J.</first-name><address><city>Sudbury</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>President and Fellows of Harvard College</orgname><role>02</role><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="232.83mm" wi="174.07mm" file="US20230000961A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="91.69mm" wi="170.43mm" file="US20230000961A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="227.84mm" wi="165.02mm" file="US20230000961A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="212.68mm" wi="107.27mm" file="US20230000961A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="207.94mm" wi="121.84mm" orientation="landscape" file="US20230000961A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="225.64mm" wi="121.33mm" file="US20230000961A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="196.43mm" wi="169.33mm" file="US20230000961A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="228.68mm" wi="88.65mm" file="US20230000961A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="218.02mm" wi="118.11mm" file="US20230000961A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="213.61mm" wi="86.53mm" file="US20230000961A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="234.61mm" wi="107.27mm" orientation="landscape" file="US20230000961A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="234.61mm" wi="107.27mm" orientation="landscape" file="US20230000961A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="224.37mm" wi="140.72mm" file="US20230000961A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="220.30mm" wi="113.54mm" file="US20230000961A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="238.51mm" wi="124.04mm" orientation="landscape" file="US20230000961A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="222.33mm" wi="130.89mm" file="US20230000961A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="212.68mm" wi="134.20mm" file="US20230000961A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="111.93mm" wi="133.60mm" file="US20230000961A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="236.81mm" wi="107.27mm" orientation="landscape" file="US20230000961A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="81.62mm" wi="146.13mm" file="US20230000961A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="228.09mm" wi="107.53mm" orientation="landscape" file="US20230000961A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="101.77mm" wi="167.98mm" file="US20230000961A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="223.77mm" wi="163.75mm" file="US20230000961A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="125.81mm" wi="140.12mm" file="US20230000961A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="236.81mm" wi="109.73mm" orientation="landscape" file="US20230000961A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="212.26mm" wi="165.61mm" file="US20230000961A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="223.18mm" wi="159.26mm" file="US20230000961A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="221.15mm" wi="175.18mm" file="US20230000961A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a continuation of U.S. patent application Ser. No. 15/935,392, filed on Mar. 26, 2018; which is a continuation of U.S. patent application Ser. No. 14/394,552, filed on Oct. 15, 2014, now U.S. Pat. No. 9,937,249, issued on Apr. 10, 2018; which is a national stage application of International Patent Application No.: PCT/US2013/036827, filed Apr. 16, 2013; which claims the benefit of U.S. Provisional Application No. 61/624,568, filed Apr. 16, 2012. The entire contents of each of the foregoing applications are hereby incorporated herein by reference.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?federal-research-statement description="Federal Research Statement" end="lead"?><heading id="h-0002" level="1">GOVERNMENT SUPPORT</heading><p id="p-0003" num="0002">This invention was made with Government support under Grant No. RO1DE019917 awarded by the National Institutes of Health. The Government has certain rights in the invention.</p><?federal-research-statement description="Federal Research Statement" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0003" level="1">SEQUENCE LISTING</heading><p id="p-0004" num="0003">The contents of the text file named &#x201c;117823-16604-Sequence_Listing.txt,&#x201d; which was created on Mar. 7, 2022 and is 5,553 bytes in size, are hereby incorporated by reference in their entirety.</p><heading id="h-0004" level="1">FIELD OF THE INVENTION</heading><p id="p-0005" num="0004">This invention relates to biocompatible injectable compositions.</p><heading id="h-0005" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0006" num="0005">Vaccines that require ex vivo manipulation of cells, such as most cell based therapy, lead to poor lymph node homing and limited efficiency.</p><heading id="h-0006" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0007" num="0006">The invention provides a solution to problems and drawbacks associated with earlier approaches. Accordingly, the invention features a composition comprising mesoporous silica (MPS) rods comprising an immune cell recruitment compound and an immune cell activation compound. The rods comprise pores of between 2-50 nm in diameter, e.g., pores of between 5-25 nm in diameter or pores of between 5-10 nm in diameter. In preferred embodiments, the rods comprise pores of approximately 8 nm in diameter. The length of the micro rods ranges from 5 &#x3bc;m to 500 &#x3bc;m. In one example, the rods comprise a length of 5-25 &#x3bc;m, e.g., 10-20 &#x3bc;m. In other examples, the rods comprise length of 50 &#x3bc;m to 250 &#x3bc;m. Robust recruitment of cells was achieved with MPS microparticle compositions characterized as having a higher aspect ratio, e.g., with rods comprising a length of 80 &#x3bc;m to 120 &#x3bc;m.</p><p id="p-0008" num="0007">Exemplary immune cell recruitment compounds include granulocyte macrophage-colony stimulating factor (GM-CSF). Other examples of recruitment compounds include chemokines, e.g., a chemokine selected from the group consisting of chemokine (C-C motif) ligand 21 (CCL-21, GenBank Accession Number: (aa) CAG29322.1 (GI:47496599), (na) EF064765.1 (GI:117606581), incorporated herein by reference), chemokine (C-C motif) ligand 19 (CCL-19, GenBank Accession Number: (aa) CAG33149.1 (GI:48145853), (na) NM_006274.2 (GI:22165424), incorporated herein by reference), as well as FMS-like tyrosine kinase 3 ligand (Flt3) ligand; Genbank Accession Number: (aa) AAI44040 (GI:219519004), (na) NM_004119 (GI: GI:121114303), incorporated herein by reference)</p><p id="p-0009" num="0008">Immune cell activating compounds include TLR agonists. Such agonists include pathogen associated molecular patterns (PAMPs), e.g., an infection-mimicking composition such as a bacterially-derived immunomodulator (a.k.a., danger signal). TLR agonists include nucleic acid or lipid compositions [e.g., monophosphoryl lipid A (MPLA)]. In one example, the TLR agonist comprises a TLR9 agonist such as a cytosine-guanosine oligonucleotide (CpG-ODN), a poly(ethylenimine) (PEI)-condensed oligonucleotide (ODN) such as PEI-CpG-ODN, or double stranded deoxyribonucleic acid (DNA). For example, the device comprises 5 &#x3bc;g, 10 &#x3bc;g, 25 &#x3bc;g, 50 &#x3bc;g, 100 &#x3bc;g, 250 &#x3bc;g, or 500 &#x3bc;g of CpG-ODN. In another example, the TLR agonist comprises a TLR3 agonist such as polyinosine-polycytidylic acid (poly I:C), PEI-poly (I:C), polyadenylic&#x2014;polyuridylic acid (poly (A:U)), PEI-poly (A:U), or double stranded ribonucleic acid (RNA). Lipopolysaccharide (LPS) is also useful for this purpose.</p><p id="p-0010" num="0009">To generate an immune response, the composition comprises an antigen to which the immune response is desired. For example, the composition comprises a tumor antigen. In preferred embodiments, the antigen comprises a tumor cell lysate (e.g., from a tumor biopsy sample that was taken from the subject to be treated). The subject is preferably a human patient, but the compositions/systems are also used for veterinary use, e.g., for treatment of companion animals such as dogs and cats as well as performance animals such as horses and livestock such as cattle, oxen, sheep, goats, and the like.</p><p id="p-0011" num="0010">Antigen presenting cells such as dendritic cells (DC's) traffick through the MPS device, i.e., the cells do not stay in the device permanently. The immune cells are recruited to the device and are present in the device temporarily while they encounter antigen and are activated Immune cells such as DC's then home to a lymph node. They accumulate in a lymph node, e.g., a draining lymph node, not in the MPS device. The accumulated cells in the lymph node further augment the immune response to the vaccine antigen resulting in a strong cellular and humoral response to the antigen.</p><p id="p-0012" num="0011">Thus, a method of inducing a systemic antigen-specific immune response to a vaccine antigen, comprises administering to a subject the MPS composition described above. The composition is loaded into a syringe and injected into the body of the recipient. For example, a small amount (e.g., 50-500 &#x3bc;l, e.g., 150 &#x3bc;l) is administered subcutaneously. Typically, the device (MPS composition) is infiltrated with cells by Day 2 post-administration, and by Day 5-7, a draining lymph node is swollen with cells that have migrated out of the device and to the lymph node tissue, where they accumulate and further propagate an antigen-specific response. The compositions are therefore useful to induce homing of immune cells to a lymph node. The MPS composition need not be removed after vaccination therapy. The composition may remain in the body at the site of administration, where it degrades. For example, the MPS particles are consumed by macrophages over time and then cleared from the body.</p><p id="p-0013" num="0012">A method of making a vaccine comprises providing a suspension of mesoporous silica rods, contacting the rods with a vaccine antigen, an immune cell recruitment compound, and an immune cell activation compound. The vaccine antigen comprises a tumor cell lysate, the recruitment compound comprises GM-CSF, and the activation compound comprises CpG ODN. In some cases, the rods are modified with glycolic acid or lactic acid prior to contacting the rods with one or more of the following compounds: vaccine antigen, recruitment compound, or activation compound. Optionally, the MPS composition/device is fabricated with MPS rods, an immune cell recruitment compound, and an immune cell activation compound (optionally, with glycolic or lactic acid modification), stored, and/or shipped to the site of use, whereupon the patient-specific tumor antigen preparation or lysate is added to the rod suspension prior to administration, e.g., 1, 2, 6, 12, 24, or 48 hours, prior to administration to the patient.</p><p id="p-0014" num="0013">The compounds that are loaded into the MPS composition are processed or purified. For example, polynucleotides, polypeptides, or other agents are purified and/or isolated. Specifically, as used herein, an &#x201c;isolated&#x201d; or &#x201c;purified&#x201d; nucleic acid molecule, polynucleotide, polypeptide, or protein, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. Purified compounds are at least 60% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. For example, a purified compound is one that is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% (w/w) of the desired compound by weight. Purity is measured by any appropriate standard method, for example, by column chromatography, thin layer chromatography, or high-performance liquid chromatography (HPLC) analysis. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of the genes or sequences that flank it in its naturally-occurring state. Purified also defines a degree of sterility that is safe for administration to a human subject, e.g., lacking infectious or toxic agents. In the case of tumor antigens, the antigen may be purified or a processed preparation such as a tumor cell lysate.</p><p id="p-0015" num="0014">Similarly, by &#x201c;substantially pure&#x201d; is meant a nucleotide or polypeptide that has been separated from the components that naturally accompany it. Typically, the nucleotides and polypeptides are substantially pure when they are at least 60%, 70%, 80%, 90%, 95%, or even 99%, by weight, free from the proteins and naturally-occurring organic molecules with they are naturally associated.</p><p id="p-0016" num="0015">A small molecule is a compound that is less than 2000 daltons in mass. The molecular mass of the small molecule is preferably less than 1000 daltons, more preferably less than 600 daltons, e.g., the compound is less than 500 daltons, 400 daltons, 300 daltons, 200 daltons, or 100 daltons.</p><p id="p-0017" num="0016">The transitional term &#x201c;comprising,&#x201d; which is synonymous with &#x201c;including,&#x201d; &#x201c;containing,&#x201d; or &#x201c;characterized by,&#x201d; is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. By contrast, the transitional phrase &#x201c;consisting of&#x201d; excludes any element, step, or ingredient not specified in the claim. The transitional phrase &#x201c;consisting essentially of&#x201d; limits the scope of a claim to the specified materials or steps &#x201c;and those that do not materially affect the basic and novel characteristic(s)&#x201d; of the claimed invention.</p><p id="p-0018" num="0017">Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All published foreign patents and patent applications cited herein are incorporated herein by reference. Genbank and NCBI submissions indicated by accession number cited herein are incorporated herein by reference. All other published references, documents, manuscripts and scientific literature cited herein are incorporated herein by reference. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0007" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is an SEM image of the MPS rods. The random stacking and self assembly of these rods generate a 3D space that allows for cell infiltration.</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a bar graph showing surface marker expression dependent on MPS rods of different lengths. 100 &#x3bc;g of the MPS rods of different lengths were incubated with bone marrow derived dendritic cells for 18 hour. As a marker of inflammation, the percentage of activated cells was determined by staining for cell surface receptors CD11c (DC marker), MHCII (antigen presentation marker) and CD86 (costimulatory receptor). The inflammatory property of the rods increased with increasing length. Since a desired scaffold exhibits inflammatory properties (similar to the PLG scaffold control), rods between 30 and 100 &#x3bc;m or 120 &#x3bc;m were used in subsequent experiments.</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIGS. <b>3</b>A-<b>3</b>C</figref> is a series of images showing the effect of MPS rods in a mouse. <figref idref="DRAWINGS">FIG. <b>3</b>A</figref> is a picture depicting a scaffold injection site excised after 7 days after 5 mg of rhodamine labeled MPS rod was injected subcutaneously into a C57b1/6j mouse. The subcutaneous pocket indicates that the rods were localized and have self-assembled to create a 3D microenvironment. <figref idref="DRAWINGS">FIG. <b>3</b>B</figref> is an SEM image of the excised scaffold site demonstrating cell infiltration into the scaffold site. <figref idref="DRAWINGS">FIG. <b>3</b>C</figref> depicts live/dead imaging of the cells detached from the MPS scaffold, demonstrating the recruitment of living cells.</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>4</b>A</figref> is a line graph showing GM-CSF release from MPS rods. 1 &#x3bc;g of GM-CSF was loaded into the MPS rods and incubated in 0.1% BSA/PBS. Supernatant was collected periodically and measured for GM-CSF using ELISA (R&#x26;D). GM-CSF is being continuously released from the MPS rods. <figref idref="DRAWINGS">FIG. <b>4</b>B</figref> is a bar graph showing surface marker expression in an in vitro bone marrow derived dendritic cell (BMDC) co-culture with MPS. 100 &#x3bc;g of the unmodified, amine-, thiol-, chloro- and phosphonate&#x2014;modified MPS rods were incubated with 10<sup>6</sup>/ml BMDCs for 18 hours. The cells were then analyzed for the expression of MHC class-II and the costimulatory molecule CD86. An increased expression of MHCII and CD86 of the BMDCs stimulated by MPS indicates that the MPS rods are inflammatory, and this property was modulated by surface-modifying the MPS rods.</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIG. <b>5</b>A</figref> is a bar graph depicting recruitment of CDs by GM-CSF loaded MPS rods. 5 mg/mouse of MPS rods loaded with or without 1 &#x3bc;g/mouse GM-CSF were injected subcutaneously. Cells from the scaffold site were retrieved and stained for the CD11c receptor (DC marker). The MPS scaffold loaded with GM-CSF was capable of recruiting more DCs than the blank MPS scaffold. <figref idref="DRAWINGS">FIG. <b>5</b>B</figref> is a bar graph depicting surface marker expression of DCs. The MPS scaffold loaded with GM-CSF and CpG-ODN activated more DCs than without CpG-ODN.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIGS. <b>6</b>A-<b>6</b>B</figref> are bar graphs showing (<figref idref="DRAWINGS">FIG. <b>6</b>A</figref>) percentage of B220+ cells or (<figref idref="DRAWINGS">FIG. <b>6</b>B</figref>) total number of B220+ cells at the scaffold site. 5 mg/mouse of MPS rods loaded with or without 1 &#x3bc;g/mouse GM-CSF, 100 &#x3bc;g CpG-ODN and 130 &#x3bc;g ovalbumin were injected subcutaneously. Cells from the scaffold site were retrieved periodically and stained for the B220 receptor (B cell marker). The MPS scaffold loaded with GM-CSF, CpG-ODN and Ova was capable of recruiting more B cells by day 3.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIGS. <b>7</b>A-<b>7</b>C</figref> are flow cytometry scatterplots (<figref idref="DRAWINGS">FIG. <b>7</b>A</figref>) and bar graphs (<figref idref="DRAWINGS">FIGS. <b>7</b>B-<b>7</b>C</figref>) depicting the presence of the MHC&#x2014;I-SIINFEKL (SEQ ID NO:1) marker on the surface of DCs. The MPS scaffold loaded with GM-CSF, CpG-ODN and the model antigen ovalbumin induced the expansion of antigen specific DCs homed to the draining lymph node (dLN). dLN cells are stained with the dendritic marker CD11c and the marker MHC&#x2014;I-SIINFEKL, which indicates that a part of the ovalbumin protein, the peptide sequence SIINFEKL, is being presented on the surface of the cell in the MHC-I complex.</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIGS. <b>8</b>A-<b>8</b>B</figref> are bar graphs showing formation of the germinal center due to the MPS scaffold. The MPS scaffold loaded with GM-CSF, CpG-ODN and the model antigen ovalbumin was able to induce the germinal center, home to activated and antigen primed B cells, in the dLN. The dLN cells are stained with B220 (B cell marker) and GL7 (germinal center marker) to investigate the formation of the germinal center, which hosts only B cells that are activated and in the process of somatic hypermutation and isotype switching.</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIGS. <b>9</b>A-<b>9</b>B</figref> are bar graphs depicting that the MPS scaffold loaded with GM-CSF, CpG-ODN and the model antigen ovalbumin was able to induce the expansion of CD8+ cytotoxic T lymphocytes (CTLs) that can specifically recognize the model antigen. Splenocytes were stained for CD8 (killer T cell marker) and with a MHCI-tetramer-SIINFEKL antibody, which indicates whether a T cell is able to recognize a specific antigen presented on the MHCI complex.</p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIGS. <b>10</b>A-<b>10</b>C</figref> are histograms showing that the MPS scaffold loaded with GM-CSF, CpG-ODN and the model antigen ovalbumin was able to induce the clonal expansion of antigen specific CD8+ CTLs in the dLN and the spleen. Injected splenocytes from the OT-I mouse were stained the cell tracker dye CFSE, whose fluorescence halves every time a cell divides. The lower fluorescence in the CFSE stained splenocytes in the spleen and the dLN in the fully loaded vaccine group indicates ova-specific CTL proliferation.</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIGS. <b>11</b>A-<b>11</b>C</figref> are histograms showing that the MPS scaffold loaded with GM-CSF, CpG-ODN and the model antigen ovalbumin was able to induce the clonal expansion of antigen specific CD4+ THs in the dLN and the spleen. Injected splenocytes from the OT-II mouse were stained the cell tracker dye CFSE, whose fluorescence halves every time a cell divides. The lower fluorescence in the CFSE stained splenocytes in the spleen and the dLN in the fully loaded vaccine group and the MPS loaded with only the antigen group indicates ova-specific CD4+TH cell proliferation.</p><p id="p-0030" num="0029"><figref idref="DRAWINGS">FIGS. <b>12</b>A-<b>12</b>B</figref> are histograms showing that antibody titer is defined as the degree to which the antibody-serum solution can be diluted and still contain a detectable amount of the antibody. The anti-ovalbumin serum antibodies were titrated. The MPS scaffold loaded with GM-CSF, CpG-ODN and ova elicited a strong and durable TH1 and TH2 antibody response. MPS loaded with OVA alone can elicit a strong TH2 response, indicating the adjuvant potential of the MPS material itself.</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIGS. <b>13</b>A-<b>13</b>B</figref> are line graphs showing that GM-CSF is released from the MPS microparticles in a controlled and sustained manner <figref idref="DRAWINGS">FIG. <b>13</b>A</figref> 1 &#x3bc;g of GM-CSF was loaded into 5 mg of MPS rods and incubated in 0.1% BSA/PBS. Supernatant was collected periodically and measured for GM-CSF using ELISA (R&#x26;D). GM-CSF was continuously released from the MPS rods, although in small quantities. <figref idref="DRAWINGS">FIG. <b>13</b>B</figref> 1 &#x3bc;g of GM-CSF was loaded into 5 mg of MPS containing OVA and CpG. It was then injected subcutaneously into C57BL/6j mice. At various time points, the tissue surrounding the injected particle scaffold was harvested and analyzed for GM-CSF level. The level of GM-CSF was maintained throughout a week.</p><p id="p-0032" num="0031"><figref idref="DRAWINGS">FIGS. <b>14</b>A-<b>14</b>B</figref> are photographs, and <figref idref="DRAWINGS">FIG. <b>14</b>C</figref> is a bar graph. Higher aspect ratio MPS microparticles recruit more cells. <figref idref="DRAWINGS">FIG. <b>14</b>A</figref> shows SEM images of MPS microparticles either between 10 &#x3bc;m and 20 &#x3bc;m or between 80 &#x3bc;m and 120 &#x3bc;m in length. The longer rods resulted in a composition with greater area or space between the rods. <figref idref="DRAWINGS">FIG. <b>14</b>B</figref> shows MPS compositions that was harvested from mice. 5 &#x3bc;g of MPS microparticles were injected subcutaneously into mice, and the scaffold site was harvested on day 7 post injection. <figref idref="DRAWINGS">FIG. <b>14</b>C</figref> is a bar graph showing enumeration of cells that were isolated from the scaffold. MPS microparticles of higher aspect ratio recruited more cells.</p><p id="p-0033" num="0032"><figref idref="DRAWINGS">FIGS. <b>15</b>A-<b>15</b>B</figref> are bar graphs. Dendritic cells (DCs) are recruited to the MPS microparticle as a response to GM-CSF. MPS microparticles were loaded with GM-CSF (0 ng, 500 ng, 1000 ng, 3000 ng) and injected subcutaneously into mice. On day 7 post injection, the scaffold was harvested and analyzed using flow cytometry. <figref idref="DRAWINGS">FIG. <b>15</b>A</figref> shows that recruited CD11c+CD11b+ DCs increases with increasing GM-CSF dose. <figref idref="DRAWINGS">FIG. <b>15</b>B</figref> shows that recruited mature CD11c+ MHCII+ DCs also DCs increases with increasing GM-CSF dose.</p><p id="p-0034" num="0033"><figref idref="DRAWINGS">FIG. <b>16</b></figref> is a bar graph showing that GM-CSF increases recruited DC trafficking to the draining LN. MPS microparticles were loaded with Alexa 647 labeled ovalbumin (OVA), or Alexa 647 labeled OVA with 1 &#x3bc;g GM-CSF, and injected subcutaneously into mice. On day 7 post injection, the draining lymph node (dLN) was harvested and analyzed using flow cytometry. With the addition of antigen (OVA), there is a modest increase of Alexa 647+CD11c+ DCs that have trafficked to the scaffold and up-taken the OVA. However, the addition of GM-CSF drastically increases DC trafficking from the scaffold to the dLN.</p><p id="p-0035" num="0034"><figref idref="DRAWINGS">FIGS. <b>17</b>A-<b>17</b>C</figref> are scatterplots and <figref idref="DRAWINGS">FIG. <b>17</b>D</figref> is a bar graph. Local delivery of CpG-ODN from the MPS microparticle scaffold increases circulation of activated DCs. MPS microparticles were loaded with 1 &#x3bc;g of GM-CSF, 300 &#x3bc;g of OVA and 100 &#x3bc;g of CpG-ODN. They were then injected subcutaneously into mice. The dLNs were harvested and analyzed after 7 days post injection. LN cells were stained with CD11c and CD86. The addition of CpG-ODN, which is locally released from the MPS scaffold, further increases the percentage and number of activated, mature DCs in the dLN.</p><p id="p-0036" num="0035"><figref idref="DRAWINGS">FIGS. <b>18</b>A-<b>18</b>C</figref> are photographs and <figref idref="DRAWINGS">FIG. <b>18</b>D</figref> is a bar graph. Proteins are released from the MPS microparticle scaffold in a controlled and sustained manner Alexa 647 labeled ovalbumin was injected subcutaneously into the flank of a mouse either in a buffer solution or loaded onto the MPS microparticles. Relative fluorescence was measured using the IVIS at various time points. If injected in a buffer solution, the protein diffuses away from the injection site in less than 1 day. However, if loaded onto the MPS microparticles, the protein is released from the local scaffold site in a sustained manner, e.g., over the course of a week (2, 3, 4, 5, 7 or more days).</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIGS. <b>19</b>A-<b>19</b>B</figref> are line graphs showing antibody titers. Antibody titer is defined as the degree to which the antibody-serum solution can be diluted and still contain a detectable amount of the antibody. Mice were vaccinated with 300 &#x3bc;g OVA, 100 &#x3bc;g CpG-ODN and 1 &#x3bc;g GM-CSF in the soluble form or loaded in 5 mg of MPS microparticles. The anti-ovalbumin serum antibodies are titrated. The MPS scaffold loaded with GM-CSF, CpG-ODN and ova can elicit a strong and durable TH1 and TH2 antibody response, as indicated by a high titer of the IgG2a and IgG1 antibody, respectively. More impressively, this response is evident beyond 200 days after vaccination with a single injection. This response was compared to OVA delivered using aluminum hydroxide, the only adjuvant approved for human use in the US. While the MPS vaccine is capable of inducing both TH1 and TH2 antibody responses, due to its capability to load small cytokines, proteins and DNAs, the response induced by alum is completely TH2 biased. The MPS vaccine is very versatile and is readily fine tuned and controlled to induce specific immune responses.</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIGS. <b>20</b>A-<b>20</b>D</figref> are scatterplots showing that vaccination with the MPS vaccine induces the expansion of T follicular helper cells. OT-II splenocytes were stained with CFSE and adoptively transferred into Thy 1.1+ recipient mice. The recipient mice were then vaccinated with MPS and lysozyme, MPS and OVA, and the full form of the vaccine containing GM-CSF and CpG. Three days after vaccination, dLN were harvested and the adoptively transferred cells were analyzed. It is shown here that mice that were vaccinated with MPS and ova, and the full form of the vaccine, generated a strong population of follicular T helper cells, which are the cells directly responsible for &#x201c;helping&#x201d; B cells to differentiate and mature into full, functional antigen specific antibody secreting plasma cells.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIGS. <b>21</b>A-<b>21</b>D</figref> are line graphs showing that vaccination with the MPS vaccine induces the clonal expansion of CD4+T helper cells. OT-II splenocytes were stained with CFSE and adoptively transferred into Thy 1.1+ recipient mice. The recipient mice were then vaccinated with MPS and lysozyme, MPS and OVA, and the full form of the vaccine containing GM-CSF and CpG. Three days after vaccination, dLN were harvested and the adoptively transferred cells were analyzed. It is shown here that both MPS and OVA, and the full vaccine, induced strong clonal expansion of the CD4+T helper cells, indicating a systemic antigen specific response.</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIGS. <b>22</b>A-<b>22</b>B</figref> are line graphs showing that glycolic acid and lactic acid modification of the MPS microparticles aids the release of bioactive GM-CSF. 1 &#x3bc;g of GM-CSF was loaded into 5 mg of glycolic acid or lactic acid modified MPS rods and incubated in 0.1% BSA/PBS. Supernatant was collected periodically and measured for GM-CSF using ELISA (R&#x26;D). Compared to GM-CSF released from unmodified MPS microparticles, glycolic acid and lactic acid modification increasecumulative release of bioactive GM-CSF by more than 20 fold.</p><p id="p-0041" num="0040"><figref idref="DRAWINGS">FIGS. <b>23</b>A-<b>23</b>D</figref> are scatterplots showing that glycolic acid modified MPS increases the percentage of recruited DCs and mature DCs. 5 mg of unmodified or glycolic acid modified MPS microparticles were loaded with 1 &#x3bc;g of GM-CSF for 1 hour at 37C, and injected subcutaneously into mice. The scaffold was harvested at day 7 and analyzed. It is evident here that the modified MPS almost doubles the percentage of recruited CD11c+CD11b+ DCs, and more drastically increases the percentage of CD11c+CD86+ mature DCs. These results indicate that the great surface modification potential of the MPS microparticles permit further manipulation of the phenotype of recruited cells to induce more potent immune responses.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0008" level="1">DETAILED DESCRIPTION</heading><p id="p-0042" num="0041">Injectable MPS-based micro-rods randomly self-assemble to form 3D scaffold in vivo. This system is designed such that it releases a cytokine to recruit and transiently house immune cells, present them with an antigen, and activate them with a danger signal. After recruitment and temporary housing or presence of the cells in the structure, these immune cells migrate out of the device structure and homed to a lymph node. Thus, the composition is one in which cells traffic/circulate in and out of, their status of immune activation being altered/modulated as a result of the trafficking through the device.</p><p id="p-0043" num="0042">A markedly expanded population of antigen specific dendritic cells was found in the lymph node as well as the formation of the germinal center, which is aided by the involvement of follicular T helper cells in the lymph node as a result of the administration of the device. A population of antigen-recognizing CD8+ CTLs in the spleen was also found to be significantly enhanced. The system also induces the clonal expansion of both antigen specific CD4 and CD8 T cells. In addition to the significant amplification of the cellular immune response, a high and durable antibody production and a balanced T<sub>H</sub>1/T<sub>H</sub>2 response was detected.</p><p id="p-0044" num="0043">Key elements of the injectable mesoporous silica micro-rod based scaffold system for modulating immune cell trafficking and reprogramming include:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0044">Aspect ratio of the MPS micro rods (10 nm cross sectional area by 100 micron length) prevents their uptake and therefore allows for local formation of a 3D structure.</li>        <li id="ul0002-0002" num="0045">8 nm pore size allows for adsorption of small molecules that can be delivered via diffusion in a controlled and continuous manner.</li>        <li id="ul0002-0003" num="0046">High surface area to volume ratio allows for the control of the loading of various cytokines, danger signal and antigen.</li>        <li id="ul0002-0004" num="0047">Inflammatory property of the MPS micro rods promotes immune cell recruitment without the need of other inflammatory cytokines.</li>        <li id="ul0002-0005" num="0048">Versatility in ability of surface chemical modification of the MPS rods that modulate properties of the rods and ways that proteins are bound to the rods.</li>        <li id="ul0002-0006" num="0049">Controlled release of GM-CSF can modulate the trafficking of immune cells to the site of the scaffold.</li>        <li id="ul0002-0007" num="0050">Controlled release of CpG-ODN activates the recruited dendritic cells.</li>        <li id="ul0002-0008" num="0051">Anchored protein antigens are taken up by the recruited immune cells at the site of the scaffold.</li>    </ul>    </li></ul></p><p id="p-0045" num="0052">A pore size of approximately 5-10, e.g., 8 nm, was found to be optimal for loading efficiency for small molecules as well as larger proteins, e.g., GM-CSF (which molecule is about 3 nm in diameter).</p><p id="p-0046" num="0053">Upon subcutaneous injection of the micro rods suspended in a buffer, the rods randomly stack into a 3D structure; the ends of the rods form physical contact with each other, and a micro space is formed between the contacts.</p><heading id="h-0009" level="2">Mps</heading><p id="p-0047" num="0054">Mesoporous silica nanoparticles are synthesized by reacting tetraethyl orthosilicate with a template made of micellar rods. The result is a collection of nano-sized spheres or rods that are filled with a regular arrangement of pores. The template can then be removed by washing with a solvent adjusted to the proper pH. In another technique, the mesoporous particle could be synthesized using a simple sol-gel method or a spray drying method. Tetraethyl orthosilicate is also used with an additional polymer monomer (as a template). Other methods include those described in U.S. Patent Publication 20120264599 and 20120256336, hereby incorporated by reference.</p><heading id="h-0010" level="2">Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)</heading><p id="p-0048" num="0055">Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a protein secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. Specifically, GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes and monocytes. Monocytes exit the blood stream, migrate into tissue, and subsequently mature into macrophages.</p><p id="p-0049" num="0056">Scaffold devices described herein comprise and release GM-CSF polypeptides to attract host DCs to the device. Contemplated GM-CSF polypeptides are isolated from endogenous sources or synthesized in vivo or in vitro. Endogenous GM-CSF polypeptides are isolated from healthy human tissue. Synthetic GM-CSF polypeptides are synthesized in vivo following transfection or transformation of template DNA into a host organism or cell, e.g. a mammal or cultured human cell line. Alternatively, synthetic GM-CSF polypeptides are synthesized in vitro by polymerase chain reaction (PCR) or other art-recognized methods Sambrook, J., Fritsch, E. F., and Maniatis, T., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY, Vol. 1, 2, 3 (1989), herein incorporated by reference).</p><p id="p-0050" num="0057">GM-CSF polypeptides are modified to increase protein stability in vivo. Alternatively, GM-CSF polypeptides are engineered to be more or less immunogenic. Endogenous mature human GM-CSF polypeptides are glycosylated, reportedly, at amino acid residues 23 (leucine), 27 (asparagine), and 39 (glutamic acid) (see U.S. Pat. No. 5,073,627). GM-CSF polypeptides of the present invention are modified at one or more of these amino acid residues with respect to glycosylation state.</p><p id="p-0051" num="0058">GM-CSF polypeptides are recombinant. Alternatively GM-CSF polypeptides are humanized derivatives of mammalian GM-CSF polypeptides. Exemplary mammalian species from which GM-CSF polypeptides are derived include, but are not limited to, mouse, rat, hamster, guinea pig, ferret, cat, dog, monkey, or primate. In a preferred embodiment, GM-CSF is a recombinant human protein (PeproTech, Catalog #300-03). Alternatively, GM-CSF is a recombinant murine (mouse) protein (PeproTech, Catalog #315-03). Finally, GM-CSF is a humanized derivative of a recombinant mouse protein.</p><p id="p-0052" num="0059">Human Recombinant GM-CSF (PeproTech, Catalog #300-03) is encoded by the following polypeptide sequence (SEQ ID NO:2):</p><p id="p-0053" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="203pt" align="left"/><tbody valign="top"><row><entry/><entry>MAPARSPSPS&#x2003;TQPWEHVNAI&#x2003;QEARRLLNLS&#x2003;RDTAAEMNET</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>VEVISEMFDL&#x2003;QEPTCLQTRL&#x2003;ELYKQGLRGS&#x2003;LTKLKGPLTM</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>MASHYKQHCP&#x2003;PTPETSCATQ&#x2003;IITFESFKEN&#x2003;LKDFLLVIPF</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>DCWEPVQE</entry></row></tbody></tgroup></table></tables></p><p id="p-0054" num="0060">Murine Recombinant GM-CSF (PeproTech, Catalog #315-03) is encoded by the following polypeptide sequence (SEQ ID NO: 3):</p><p id="p-0055" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="203pt" align="left"/><tbody valign="top"><row><entry/><entry>MAPTRSPITV&#x2003;TRPWKHVEAI&#x2003;KEALNLLDDM&#x2003;PVTLNEEVEV</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>VSNEFSFKKL&#x2003;TCVQTRLKIF&#x2003;EQGLRGNFTK&#x2003;LKGALNMTAS</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>YYQTYCPPTP&#x2003;ETDCETQVTT&#x2003;YADFIDSLKT&#x2003;FLTDIPFECK</entry></row><row><entry/><entry> </entry></row><row><entry/><entry>KPVQK</entry></row></tbody></tgroup></table></tables></p><p id="p-0056" num="0061">Human Endogenous GM-CSF is encoded by the following mRNA sequence (NCBI Accession No. NM_000758 and SEQ ID NO: 4):</p><p id="p-0057" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="28pt" align="char"/><colspec colname="2" colwidth="189pt" align="left"/><tbody valign="top"><row><entry>1</entry><entry>acacagagag&#x2003;aaaggctaaa&#x2003;gttctctgga&#x2003;ggatgtggct</entry></row><row><entry> </entry></row><row><entry/><entry>gcagagcctg&#x2003;ctgctcttgg</entry></row><row><entry> </entry></row><row><entry>61</entry><entry>gcactgtggc&#x2003;ctgcagcatc&#x2003;tctgcacccg&#x2003;cccgctcgcc</entry></row><row><entry> </entry></row><row><entry/><entry>cagccccagc&#x2003;acgcagccct</entry></row><row><entry> </entry></row><row><entry>121</entry><entry>gggagcatgt&#x2003;gaatgccatc&#x2003;caggaggccc&#x2003;ggcgtctcct</entry></row><row><entry> </entry></row><row><entry/><entry>gaacctgagt&#x2003;agagacactg</entry></row><row><entry> </entry></row><row><entry>181</entry><entry>ctgctgagat&#x2003;gaatgaaaca&#x2003;gtagaagtca&#x2003;tctcagaaat</entry></row><row><entry> </entry></row><row><entry/><entry>gtttgacctc&#x2003;caggagccga</entry></row><row><entry> </entry></row><row><entry>241</entry><entry>cctgcctaca&#x2003;gacccgcctg&#x2003;gagctgtaca&#x2003;agcagggcct</entry></row><row><entry> </entry></row><row><entry/><entry>gcggggcagc&#x2003;ctcaccaagc</entry></row><row><entry> </entry></row><row><entry>301</entry><entry>tcaagggccc&#x2003;cttgaccatg&#x2003;atggccagcc&#x2003;actacaagca</entry></row><row><entry> </entry></row><row><entry/><entry>gcactgccct&#x2003;ccaaccccgg</entry></row><row><entry> </entry></row><row><entry>361</entry><entry>aaacttcctg&#x2003;tgcaacccag&#x2003;attatcacct&#x2003;ttgaaagttt</entry></row><row><entry> </entry></row><row><entry/><entry>caaagagaac&#x2003;ctgaaggact</entry></row><row><entry> </entry></row><row><entry>421</entry><entry>ttctgcttgt&#x2003;catccccttt&#x2003;gactgctggg&#x2003;agccagtcca</entry></row><row><entry> </entry></row><row><entry/><entry>ggagtgagac&#x2003;cggccagatg</entry></row><row><entry> </entry></row><row><entry>481</entry><entry>aggctggcca&#x2003;agccggggag&#x2003;ctgctctctc&#x2003;atgaaacaag</entry></row><row><entry> </entry></row><row><entry/><entry>agctagaaac&#x2003;tcaggatggt</entry></row><row><entry> </entry></row><row><entry>541</entry><entry>catcttggag&#x2003;ggaccaaggg&#x2003;gtgggccaca&#x2003;gccatggtgg</entry></row><row><entry> </entry></row><row><entry/><entry>gagtggcctg&#x2003;gacctgccct</entry></row><row><entry> </entry></row><row><entry>601</entry><entry>gggccacact&#x2003;gaccctgata&#x2003;caggcatggc&#x2003;agaagaatgg</entry></row><row><entry> </entry></row><row><entry/><entry>gaatatttta&#x2003;tactgacaga</entry></row><row><entry> </entry></row><row><entry>661</entry><entry>aatcagtaat&#x2003;atttatatat&#x2003;ttatattttt&#x2003;aaaatattta</entry></row><row><entry> </entry></row><row><entry/><entry>tttatttatt&#x2003;tatttaagtt</entry></row><row><entry> </entry></row><row><entry>721</entry><entry>catattccat&#x2003;atttattcaa&#x2003;gatgttttac&#x2003;cgtaataatt</entry></row><row><entry> </entry></row><row><entry/><entry>attattaaaa&#x2003;atatgcttct</entry></row><row><entry> </entry></row><row><entry>781</entry><entry>a</entry></row></tbody></tgroup></table></tables></p><p id="p-0058" num="0062">Human Endogenous GM-CSF is encoded by the following amino acid sequence (NCBI Accession No. NP_000749.2 and SEQ ID NO: 5):</p><p id="p-0059" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="left"/><tbody valign="top"><row><entry>MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTA</entry></row><row><entry> </entry></row><row><entry>AEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASH</entry></row><row><entry> </entry></row><row><entry>YKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE</entry></row></tbody></tgroup></table></tables></p><heading id="h-0011" level="2">Cytosine-Guanosine (CpG) Oligonucleotide (CpG-ODN) Sequences</heading><p id="p-0060" num="0063">CpG sites are regions of deoxyribonucleic acid (DNA) where a cysteine nucleotide occurs next to a guanine nucleotide in the linear sequence of bases along its length (the &#x201c;p&#x201d; represents the phosphate linkage between them and distinguishes them from a cytosine-guanine complementary base pairing). CpG sites play a pivotal role in DNA methylation, which is one of several endogenous mechanisms cells use to silence gene expression. Methylation of CpG sites within promoter elements can lead to gene silencing. In the case of cancer, it is known that tumor suppressor genes are often silenced while oncogenes, or cancer-inducing genes, are expressed. CpG sites in the promoter regions of tumor suppressor genes (which prevent cancer formation) have been shown to be methylated while CpG sites in the promoter regions of oncogenes are hypomethylated or unmethylated in certain cancers. The TLR-9 receptor binds unmethylated CpG sites in DNA.</p><p id="p-0061" num="0064">The vaccine composition described herein comprises CpG oligonucleotides. CpG oligonucleotides are isolated from endogenous sources or synthesized in vivo or in vitro. Exemplary sources of endogenous CpG oligonucleotides include, but are not limited to, microorganisms, bacteria, fungi, protozoa, viruses, molds, or parasites. Alternatively, endogenous CpG oligonucleotides are isolated from mammalian benign or malignant neoplastic tumors. Synthetic CpG oligonucleotides are synthesized in vivo following transfection or transformation of template DNA into a host organism. Alternatively, Synthetic CpG oligonucleotides are synthesized in vitro by polymerase chain reaction (PCR) or other art-recognized methods (Sambrook, J., Fritsch, E. F., and Maniatis, T., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY, Vol. 1, 2, 3 (1989), herein incorporated by reference).</p><p id="p-0062" num="0065">CpG oligonucleotides are presented for cellular uptake by dendritic cells. For example, naked CpG oligonucleotides are used. The term &#x201c;naked&#x201d; is used to describe an isolated endogenous or synthetic polynucleotide (or oligonucleotide) that is free of additional substituents. In another embodiment, CpG oligonucleotides are bound to one or more compounds to increase the efficiency of cellular uptake. Alternatively, or in addition, CpG oligonucleotides are bound to one or more compounds to increase the stability of the oligonucleotide within the scaffold and/or dendritic cell. CpG oligonucleotides are optionally condensed prior to cellular uptake. For example, CpG oligonucleotides are condensed using polyethylimine (PEI), a cationic polymer that increases the efficiency of cellular uptake into dendritic cells.</p><p id="p-0063" num="0066">CpG oligonucleotides can be divided into multiple classes. For example, exemplary CpG-ODNs encompassed by compositions, methods and devices of the present invention are stimulatory, neutral, or suppressive. The term &#x201c;stimulatory&#x201d; describes a class of CpG-ODN sequences that activate TLR9. The term &#x201c;neutral&#x201d; describes a class of CpG-ODN sequences that do not activate TLR9. The term &#x201c;suppressive&#x201d; describes a class of CpG-ODN sequences that inhibit TLR9. The term &#x201c;activate TLR9&#x201d; describes a process by which TLR9 initiates intracellular signaling.</p><p id="p-0064" num="0067">Stimulatory CpG-ODNs can further be divided into three types A, B and C, which differ in their immune-stimulatory activities. Type A stimulatory CpG ODNs are characterized by a phosphodiester central CpG-containing palindromic motif and a phosphorothioate 3&#x2032; poly-G string. Following activation of TLR9, these CpG ODNs induce high IFN-&#x3b1; production from plasmacytoid dendritic cells (pDC). Type A CpG ODNs weakly stimulate TLR9-dependent NF-&#x3ba;B signaling.</p><p id="p-0065" num="0068">Type B stimulatory CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides. Following TLR9 activation, these CpG-ODNs strongly activate B cells. In contrast to Type A CpG-ODNs, Type B CpG-ODNS weakly stimulate IFN-&#x3b1; secretion.</p><p id="p-0066" num="0069">Type C stimulatory CpG ODNs comprise features of Types A and B. Type C CpG-ODNs contain a complete phosphorothioate backbone and a CpG containing palindromic motif. Similar to Type A CpG ODNs, Type C CpG ODNs induce strong IFN-&#x3b1; production from pDC. Similar to Type B CpG ODNs, Type C CpG ODNs induce strong B cell stimulation.</p><p id="p-0067" num="0070">Exemplary stimulatory CpG ODNs comprise, but are not limited to, ODN 1585, ODN 1668, ODN 1826, ODN 2006, ODN 2006-G5, ODN 2216, ODN 2336, ODN 2395, ODN M362 (all InvivoGen). The present invention also encompasses any humanized version of the preceding CpG ODNs. In one preferred embodiment, compositions, methods, and devices of the present invention comprise ODN 1826 (the sequence of which from 5&#x2032; to 3&#x2032; is tccatgacgttcctgacgtt, wherein CpG elements are bolded, SEQ ID NO: 10).</p><p id="p-0068" num="0071">Neutral, or control, CpG ODNs that do not stimulate TLR9 are encompassed by the present invention. These ODNs comprise the same sequence as their stimulatory counterparts but contain GpC dinucleotides in place of CpG dinucleotides.</p><p id="p-0069" num="0072">Exemplary neutral, or control, CpG ODNs encompassed by the present invention comprise, but are not limited to, ODN 1585 control, ODN 1668 control, ODN 1826 control, ODN 2006 control, ODN 2216 control, ODN 2336 control, ODN 2395 control, ODN M362 control (all InvivoGen). The present invention also encompasses any humanized version of the preceding CpG ODNs.</p><heading id="h-0012" level="2">Antigens</heading><p id="p-0070" num="0073">Compositions, methods, and devices described herein comprise tumor antigens or other antigens. Antigens elicit protective immunity or generate a therapeutic immune response in a subject to whom such a device was administered. Preferred tumor antigens are tumor cell lysates (see, e.g., Ali et. Al., 2009, Nature Materials 8, 151-158; hereby incorporated by reference). For example, a whole tumor or tumor biopsy sample is extracted from a human patient (or non-human animal), and digested using collagenase to degrade the extra cellular matrix. Then the tumor cells then undergo three cycles of the freeze thaw process, in which the cells are frozen in liquid N<sub>2 </sub>and then thawed in a water bath. This process generates the tumor antigens, which are then loaded onto the MPS particles at the same time with GM-CSF and CpG ODN. For example, a vaccine dose of tumor cell lysate antigen is the amount obtained from 1&#xd7;10<sup>6 </sup>tumor cells. After fabrication of the MPS particles, the particles are suspended in a physiologically accepted buffer, e.g., PBS, and the recruitment compound (e.g., GM-CSF), activating compound (e.g., CpG), and antigen added to the suspension of rods. The mixture is shaken at room temperature overnight and then lyophilized for about 4 hours. Prior to administration, the rods are again suspended in buffer and the suspension loaded into a 1 ml syringe (18 gauge needle). A typical vaccine dose is 150 &#x3bc;l of the mixture per injection.</p><p id="p-0071" num="0074">Exemplary cancer antigens encompassed by the compositions, methods, and devices of the present invention include, but are not limited to, tumor lysates extracted from biopsies, irradiated tumor cells, MAGE series of antigens (MAGE-1 is an example), MART-1/melana, tyrosinase, ganglioside, gp100, GD-2, O-acetylated GD-3, GM-2, MUC-1, Sos1, Protein kinase C-binding protein, Reverse transcriptase protein, AKAP protein, VRK1, KIAA1735, T7-1, T11-3, T11-9, <i>Homo Sapiens </i>telomerase ferment (hTRT), Cytokeratin-19 (CYFRA21-1), SQUAMOUS CELL CARCINOMA ANTIGEN 1 (SCCA-1), (PROTEIN T4-A), SQUAMOUS CELL CARCINOMA ANTIGEN 2 (SCCA-2), Ovarian carcinoma antigen CA125 (1A1-3B) (KIAA0049), MUCIN 1 (TUMOR-ASSOCIATED MUCIN), (CARCINOMA-ASSOCIATED MUCIN), (POLYMORPHIC EPITHELIAL MUCIN),(PEM),(PEMT),(EPISIALIN), (TUMOR-ASSOCIATED EPITHELIAL MEMBRANE ANTIGEN),(EMA),(H23AG), (PEANUT-REACTIVE URINARY MUCIN), (PUM), (BREAST CARCINOMA&#x2014;ASSOCIATED ANTIGEN DF3), CTCL tumor antigen se1-1, CTCL tumor antigen se14-3, CTCL tumor antigen se20-4, CTCL tumor antigen se20-9, CTCL tumor antigen se33-1, CTCL tumor antigen se37-2, CTCL tumor antigen se57-1, CTCL tumor antigen se89-1, Prostate-specific membrane antigen, 5T4 oncofetal trophoblast glycoprotein, Orf73 Kaposi's sarcoma-associated herpesvirus, MAGE-C1 (cancer/testis antigen CT7), MAGE-B1 ANTIGEN (MAGE-XP ANTIGEN) (DAM10), MAGE-B2 ANTIGEN (DAM6), MAGE-2 ANTIGEN, MAGE-4a antigen, MAGE-4b antigen, Colon cancer antigen NY&#x2014;CO-45, Lung cancer antigen NY-LU-12 variant A, Cancer associated surface antigen, Adenocarcinoma antigen ART1, Paraneoplastic associated brain-testis-cancer antigen (onconeuronal antigen MA2; paraneoplastic neuronal antigen), Neuro-oncological ventral antigen 2 (NOVA2), Hepatocellular carcinoma antigen gene 520, TUMOR-ASSOCIATED ANTIGEN CO-029, Tumor-associated antigen MAGE-X2, Synovial sarcoma, X breakpoint 2, Squamous cell carcinoma antigen recognized by T cell, Serologically defined colon cancer antigen 1, Serologically defined breast cancer antigen NY&#x2014;BR-15, Serologically defined breast cancer antigen NY&#x2014;BR-16, Chromogranin A; parathyroid secretory protein 1, DUPAN-2, CA 19-9, CA 72-4, CA 195, Carcinoembryonic antigen (CEA). Purified tumor antigens are used alone or in combination with one another.</p><p id="p-0072" num="0075">The system is also useful to generate an immune response to other antigens such as microbial pathogens (e.g., bacteria, viruses, fungi).</p><p id="p-0073" num="0076">The following materials and methods were used to generate the data described herein.</p><heading id="h-0013" level="2">MPS Scaffold Fabrication</heading><p id="p-0074" num="0077">The Pluronic P-123 (Sigma-Aldrich) surfactant was dissolved in 1.6M HCl at room temperature, and heated 40 degrees C. 42 mmol of Tetraethyl orthosilicate (TEOS) (Sigma-Aldrich) was added and heated for 20 hours at 40 degrees C. under stirring (600 rpm). The composition was then heated to 100 degrees C. for 24 hours. The rod particles were collected by filtration and air dried at room temperature. The particles were extracted in ethanol/HCl (5 parts HCl to 500 parts EtOH) overnight at 80 degrees C. Alternatively, the particles were calcined at 550 degrees C. for 4 hours in 100% ethanol. The MPS composition may be stored and shipped for use before or after adding recruitment and/or activation compounds and before or after adding antigen. For example, if antigen is a tumor cells lysate made from a biopsy sample taken from a patient, it may be processed and added to MPS particles shortly before administration to the patient.</p><p id="p-0075" num="0078">For full vaccine composition, 1 &#x3bc;g/mouse GM-CSF, 100 &#x3bc;g/mouse CpG-ODN and 130 &#x3bc;g/mouse of the ovalbumin protein were incubated with 5 mg/mouse MPS in dH<sub>2</sub>O for 12 hours, lyophilized for 12 hours, resuspended in 150 &#x3bc;l/mouse PBS and injected subcutaneously using a 18G needle.</p><p id="p-0076" num="0079">To determine the release kinetics of GM-CSF, and CpG-ODN from the MPS rods, radioactive I-labeled recombinant human GM-CSF was used as a tracer, and standard release studies were carried out. Similarly, the amount of CpG-ODN released into PBS was determined by the absorbance readings using a Nanodrop instrument (ND1000, Nanodrop Technologies).</p><heading id="h-0014" level="2">Modification of MPS Microparticles</heading><p id="p-0077" num="0080">Standard 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry is used to activate a carboxylic acid on glycolic acid or lactic acid. The MPS particles are amine modified using amine propyl silane. The two components are then mixed together at room temperature overnight to react. The particles are then allowed to air dry. The resulting glycolic acid and/or lactic acid modified particles are then contacted with GM-CSF or other compounds as described above.</p><heading id="h-0015" level="2">In Vitro DC Activation Assay</heading><p id="p-0078" num="0081">Murine Dendritic Cells (DCs) were differentiated from the bone marrow cells using 20 ng/ml GM-CSF. Differentiated DCs, at 10<sup>6</sup>/ml, were incubated with 100 &#x3bc;g/ml of the MPS particles for 18 hours, and analyzed for the expression of CD11c (ebiosciences, San Diego, Calif.), CD86 (ebiosciences, San Diego, Calif.) and MHC class-II (ebiosciences, San Diego, Calif.) using flow cytometry.</p><heading id="h-0016" level="2">Analysis of DC Recruitment to MPS Scaffold and Emigration to Lymph Nodes</heading><p id="p-0079" num="0082">The MPS scaffold was retrieved from the animal and digested by mechanically separating the cells from the rods. APC conjugated CD11c (dendritic cell marker), FITC conjugated MHC class-II, and PE conjugated CD86 (B7, costimulatory molecule) stains were used for DC and leukocyte recruitment analysis. Cells were gated according to positive fluorescein isothiocyanate (FITC), Allophycocyanin (APC) and phycoerythrin (PE) using isotype controls, and the percentage of cells staining positive for each surface antigen was recorded.</p><p id="p-0080" num="0083">To determine the presence of antigen specific DCs in the lymph nodes, the draining lymph node (dLN) was harvested and analyzed using APC conjugated CD11c and PE conjugated SIINFEKL-MHC class-I (ebiosciences, San Diego, Calif.).</p><heading id="h-0017" level="2">Analysis of Antigen Specific CD8+ Spleen T Cells</heading><p id="p-0081" num="0084">The spleen was harvested and digested. After lysing the red blood cells, the splenocytes were analyzed using PE-CY7 conjugated CD3 (ebiosciences, San Diego, Calif.), APC conjugated CD8 (ebiosciences, San Diego, Calif.) and the PE conjugated SIINFEKL (SEQ ID NO:) MHC class-I tetramer (Beckman Coulter). SIINFEKL is an ovalbumin derived peptide [OVA(257-264)].</p><heading id="h-0018" level="2">Analysis of CD4+ or CD8+ T Cell Clonal Expansion</heading><p id="p-0082" num="0085">The spleens from the OT-II (for CD4) or OT-I (for CD8) transgenic C57b1/6 mice (Jackson Laboratories) were harvested, digested, pooled and stained with the cell tracer Carboxyfluorescein succinimidyl ester (CFSE). 20&#xd7;10<sup>6 </sup>stained splenocytes/mouse were IV injected into the C57b1/6 (Jackson Laboratories) mice two days post immunization. The dLNs and spleens were retrieved after four days post IV injection and analyzed using PE conjugated CD8 or CD4 marker.</p><heading id="h-0019" level="2">Characterization of Anti-OVA Humoral Response</heading><p id="p-0083" num="0086">Blood sera were analyzed for IgG1, and IgG2a antibodies by ELISA using ovalbumin-coated plates. Antibody titration was defined as the lowest serum dilution at which the ELISA OD reading is &#x3e;0.3 (blank).</p><heading id="h-0020" level="1">OTHER EMBODIMENTS</heading><p id="p-0084" num="0087">While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.</p><p id="p-0085" num="0088">The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. Genbank and NCBI submissions indicated by accession number cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.</p><p id="p-0086" num="0089">While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000961A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-01-18" num="01-18"><claim-text><b>1</b>.-<b>18</b>. (canceled)</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. A method of inducing a systemic antigen-specific immune response to a vaccine antigen, comprising administering to a subject a composition comprising:<claim-text>mesoporous silica rods, wherein the mesoporous silica rods have a length of between 5 &#x3bc;m to 500 &#x3bc;m, and wherein the mesoporous silica rods comprise pores of between 2-50 nm in diameter; and</claim-text><claim-text>an inflammatory cytokine that recruits an immune cell to the mesoporous silica rods,</claim-text><claim-text>wherein the inflammatory cytokine is loaded into the mesoporous silica rods and is released from the mesoporous silica rods upon administration to a subject, and</claim-text><claim-text>wherein the mesoporous silica rods are capable of self-assembly in vivo into a three-dimensional scaffold that allows for immune cell infiltration.</claim-text></claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. A method of inducing homing of vaccine antigen-specific immune cells to a lymph node, comprising administering to a subject a composition comprising:<claim-text>mesoporous silica rods, wherein the mesoporous silica rods have a length of between 5 &#x3bc;m to 500 &#x3bc;m, and wherein the mesoporous silica rods comprise pores of between 2-50 nm in diameter; and</claim-text><claim-text>an inflammatory cytokine that recruits an immune cell to the mesoporous silica rods,</claim-text><claim-text>wherein the inflammatory cytokine is loaded into the mesoporous silica rods and is released from the mesoporous silica rods upon administration to a subject, and</claim-text><claim-text>wherein the mesoporous silica rods are capable of self-assembly in vivo into a three-dimensional scaffold that allows for immune cell infiltration.</claim-text></claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the mesoporous silica rods comprise pores of between 5-25 nm in diameter.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the mesoporous silica rods comprise pores of between 5-10 nm in diameter.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the mesoporous silica rods comprise pores of approximately 8 nm in diameter.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the mesoporous silica rods have a length of 5 &#x3bc;m to 25 &#x3bc;m.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the mesoporous silica rods have a length of 80 &#x3bc;m to 120 &#x3bc;m.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the inflammatory cytokine comprises granulocyte macrophage-colony stimulating factor (GM-CSF), chemokine (C-C motif) ligand 21 (CCL-21), chemokine (C-C motif) ligand 19 (CCl-19), or a FMS-like tyrosine kinase 3 (Flt-3) ligand.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the inflammatory cytokine comprises GM-CSF.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the composition further comprises a vaccine antigen.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. The method of <claim-ref idref="CLM-00028">claim 28</claim-ref>, wherein the vaccine antigen comprises a tumor antigen.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The method of <claim-ref idref="CLM-00029">claim 29</claim-ref>, wherein the tumor antigen is selected from the group consisting of MAGE-1, MART-1/melana, tyrosinase, ganglioside, gp100, GD-2, O-acetylated GD-3, GM-2, Mucin 1, Sos1, protein kinase C-binding protein, reverse transcriptase protein, AKAP protein, VRK1, KIAA1735, T7-1, T11-3, T11-9, <i>Homo sapiens </i>telomerase ferment (hTRT), Cytokeratin-19 (CYFRA21-1), squamous cell carcinoma antigen 1 (SCCA-1), Protein T4-A, squamous cell carcinoma antigen 2 (SCCA-2), ovarian carcinoma antigen CA125 (1A1-3B) (KIAA0049), CTCL tumor antigen se1-1, CTCL tumor antigen se14-3, CTCL tumor antigen se20-4, CTCL tumor antigen se20-9, CTCL tumor antigen se33-1, CTCL tumor antigen se37-2, CTCL tumor antigen se57-1, CTCL tumor antigen se89-1, prostate specific membrane antigen, 5T4 oncofetal trophoblast glycoprotein, Orf73 Kaposi's sarcoma-associated herpesvirus, MAGE-C1 (cancer/testis antigen CT7), MAGE-B1 Antigen (MAGE-XP Antigen), DAM10, MAGE-B2 Antigen (DAM6), MAGE-2 Antigen, MAGE-4a antigen, MAGE-4b antigen, colon cancer antigen NY&#x2014;CO-45, lung cancer antigen NY-LU-12 variant A, cancer associated surface antigen, adenocarcinoma antigen ART1, paraneoplastic associated brain-testis-cancer antigen, onconeuronal antigen MA2, paraneoplastic neuronal antigen, neuro oncological ventral antigen 2 (NOVA2), hepatocellular carcinoma antigen gene 520, tumor-associated antigen CO-029, tumor-associated antigen MAGE-X2, synovial sarcoma, X breakpoint 2, squamous cell carcinoma antigen recognized by T cell, seriologically defined colon cancer antigen 1, seriologically defined breast cancer antigen NY&#x2014;BR-15, seriologically defined breast cancer antigen NY&#x2014;BR-16, Chromogranin A, parathyroid secretory protein 1, DUPAN-2, CA 19-9, CA 72-4, CA 195, and carcinoembryonic antigen (CEA).</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the composition further comprises an immune cell activation compound.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The method of <claim-ref idref="CLM-00031">claim 31</claim-ref>, wherein the immune cell activation compound comprises a TLR agonist.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. The method of <claim-ref idref="CLM-00032">claim 32</claim-ref>, wherein the TLR agonist comprises CpG ODN.</claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. The composition of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the composition comprises an immune cell activation compound and an antigen.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. The composition of <claim-ref idref="CLM-00034">claim 34</claim-ref>, wherein the inflammatory cytokine comprises GM-CSF, the immune cell activation compound comprises CpG-ODN, and the antigen comprises a tumor antigen.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the mesoporous silica rods are modified with a chemical group or a compound selected from the group consisting of an amine group, thiol group, chloro group, phosphonate group, glycolic acid, and lactic acid.</claim-text></claim><claim id="CLM-00037" num="00037"><claim-text><b>37</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the subject is a human.</claim-text></claim><claim id="CLM-00038" num="00038"><claim-text><b>38</b>. The method of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the composition is administered by injection.</claim-text></claim></claims></us-patent-application>